<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64430</article-id><article-id pub-id-type="doi">10.7554/eLife.64430</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>GSK3 inhibition rescues growth and telomere dysfunction in dyskeratosis congenita iPSC-derived type II alveolar epithelial cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-213005"><name><surname>Fernandez</surname><given-names>Rafael Jesus</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9295-4810</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213006"><name><surname>Gardner</surname><given-names>Zachary JG</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213007"><name><surname>Slovik</surname><given-names>Katherine J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213008"><name><surname>Liberti</surname><given-names>Derek C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2991-9283</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213009"><name><surname>Estep</surname><given-names>Katrina N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213010"><name><surname>Yang</surname><given-names>Wenli</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213011"><name><surname>Chen</surname><given-names>Qijun</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213012"><name><surname>Santini</surname><given-names>Garrett T</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213013"><name><surname>Perez</surname><given-names>Javier V</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213014"><name><surname>Root</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213015"><name><surname>Bhatia</surname><given-names>Ranvir</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213016"><name><surname>Tobias</surname><given-names>John W</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-137324"><name><surname>Babu</surname><given-names>Apoorva</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-137323"><name><surname>Morley</surname><given-names>Michael P</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213017"><name><surname>Frank</surname><given-names>David B</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-55645"><name><surname>Morrisey</surname><given-names>Edward E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5785-1939</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-91770"><name><surname>Lengner</surname><given-names>Christopher J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0574-5189</contrib-id><email>lengner@vet.upenn.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-213018"><name><surname>Johnson</surname><given-names>F Brad</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7443-7227</contrib-id><email>johnsonb@pennmedicine.upenn.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Medical Scientist Training Program, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Cell and Molecular Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Institute for Regenerative Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Department of Medicine, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>College of Arts and Sciences and Vagelos Scholars Program, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Penn Genomic Analysis Core, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Penn Cardiovascular Institute, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Penn-CHOP Lung Biology Institute, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01z7r7q48</institution-id><institution>Division of Pediatric Cardiology, Department of Pediatrics, Children's Hospital of Philadelphia</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Institute on Aging, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dang</surname><given-names>Weiwei</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Baylor College of Medicine</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Tyler</surname><given-names>Jessica K</given-names></name><role>Senior Editor</role><aff><institution>Weill Cornell Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e64430</elocation-id><history><date date-type="received" iso-8601-date="2020-10-28"><day>28</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2022-05-11"><day>11</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2020-10-28"><day>28</day><month>10</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.10.28.358887"/></event></pub-history><permissions><copyright-statement>© 2022, Fernandez et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Fernandez et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64430-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-64430-figures-v2.pdf"/><abstract><p>Dyskeratosis congenita (DC) is a rare genetic disorder characterized by deficiencies in telomere maintenance leading to very short telomeres and the premature onset of certain age-related diseases, including pulmonary fibrosis (PF). PF is thought to derive from epithelial failure, particularly that of type II alveolar epithelial (AT2) cells, which are highly dependent on Wnt signaling during development and adult regeneration. We use human induced pluripotent stem cell-derived AT2 (iAT2) cells to model how short telomeres affect AT2 cells. Cultured DC mutant iAT2 cells accumulate shortened, uncapped telomeres and manifest defects in the growth of alveolospheres, hallmarks of senescence, and apparent defects in Wnt signaling. The GSK3 inhibitor, CHIR99021, which mimics the output of canonical Wnt signaling, enhances telomerase activity and rescues the defects. These findings support further investigation of Wnt agonists as potential therapies for DC-related pathologies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>dyskeratosis congenita</kwd><kwd>type II alveolar epithelial cells</kwd><kwd>pulmonary fibrosis</kwd><kwd>Wnt</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R21AG054209</award-id><principal-award-recipient><name><surname>Lengner</surname><given-names>Christopher J</given-names></name><name><surname>Johnson</surname><given-names>F Brad</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>5T32AG000255</award-id><principal-award-recipient><name><surname>Fernandez</surname><given-names>Rafael Jesus</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Team Telomere/Penn Orphan Disease Center</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lengner</surname><given-names>Christopher J</given-names></name><name><surname>Johnson</surname><given-names>F Brad</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL148821</award-id><principal-award-recipient><name><surname>Lengner</surname><given-names>Christopher J</given-names></name><name><surname>Johnson</surname><given-names>F Brad</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Telomere dysfunction in iPSC-derived type II alveolar epithelial cells causes senescence and gene expression changes including Wnt-related changes that GSK3 inhibition can rescue, providing insight into pulmonary fibrosis pathogenesis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Dyskeratosis congenita (DC) is a rare genetic disorder characterized by bone marrow failure, skin abnormalities, elevated risk of certain cancers, and liver and pulmonary fibrosis (PF). These pathologies are caused by abnormally shortened and uncapped telomeres arising from deficiencies in telomere maintenance, typically due to defects in the action of telomerase. Significant progress has been made in treating the bone marrow failure of DC patients, particularly via transplantation, but PF remains a major life-limiting pathology (<xref ref-type="bibr" rid="bib2">Agarwal, 2018</xref>; <xref ref-type="bibr" rid="bib20">Dietz et al., 2011</xref>).</p><p>PF is a subtype of interstitial pneumonia that is chronic and progressive, replacing the normal lace-like alveolar architecture with patchy, hyperproliferative fibrous tissue (<xref ref-type="bibr" rid="bib58">Lederer and Martinez, 2018</xref>). Current therapies are only modestly effective and do not reverse the underlying fibrosis, and lung transplantation is not always an option (<xref ref-type="bibr" rid="bib47">King et al., 2014</xref>; <xref ref-type="bibr" rid="bib58">Lederer and Martinez, 2018</xref>; <xref ref-type="bibr" rid="bib88">Richeldi et al., 2014</xref>; <xref ref-type="bibr" rid="bib107">Valapour et al., 2020</xref>). While much of the early work in PF pathogenesis focused on unraveling the contributions of fibroblasts, genetic studies of families with a predisposition to PF argue that defects in alveolar epithelial cells and telomeres are key drivers of disease (<xref ref-type="bibr" rid="bib4">Alder et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Armanios et al., 2007</xref>; <xref ref-type="bibr" rid="bib12">Bullard et al., 2005</xref>; <xref ref-type="bibr" rid="bib19">Cogan et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Haschek and Witschi, 1979</xref>; <xref ref-type="bibr" rid="bib53">Kropski et al., 2015</xref>; <xref ref-type="bibr" rid="bib68">Maitra et al., 2010</xref>; <xref ref-type="bibr" rid="bib104">Thomas et al., 2002</xref>; <xref ref-type="bibr" rid="bib111">Wang et al., 2009</xref>). Recent work in mice shows that dysfunctional type II alveolar epithelial (AT2) cells, the putative stem cells of alveoli (<xref ref-type="bibr" rid="bib9">Barkauskas et al., 2013</xref>), can lead to a progressive chronic fibrotic response similar to that seen in patients (<xref ref-type="bibr" rid="bib76">Nureki et al., 2018</xref>). Furthermore, many of the same genes which when mutated cause DC have also been linked to familial PF (<xref ref-type="bibr" rid="bib4">Alder et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Armanios et al., 2007</xref>; <xref ref-type="bibr" rid="bib19">Cogan et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Kropski et al., 2017</xref>). In sporadic PF, both age and short telomeres are risk factors, and these risks are linked because age is associated with telomere shortening in the lung, particularly in AT2 cells (<xref ref-type="bibr" rid="bib3">Alder et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Everaerts et al., 2018</xref>). Consistent with a role for telomere dysfunction in driving PF, AT2 cells in sporadic PF express hallmarks of senescence and have shorter telomeres in fibrotic regions than those in non-fibrotic regions (<xref ref-type="bibr" rid="bib21">Disayabutr et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Kropski et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Snetselaar et al., 2017</xref>). Additionally, two human Mendelian randomization studies argue that short telomeres are a cause of PF (<xref ref-type="bibr" rid="bib25">Duckworth et al., 2020</xref>; <xref ref-type="bibr" rid="bib102">Telomeres Mendelian Randomization Collaboration et al., 2017</xref>). Murine studies also argue that telomere dysfunction and senescence in AT2 cells can drive PF (<xref ref-type="bibr" rid="bib75">Naikawadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib84">Povedano et al., 2015</xref>; <xref ref-type="bibr" rid="bib116">Yao et al., 2019</xref>). Although causality is thus evident, exactly how AT2 cell telomere dysfunction leads to PF is poorly understood.</p><p>Previous work in our lab using mouse and human induced pluripotent stem (iPS) cell-derived organoid models of DC intestinal defects uncovered a positive feedback loop by which telomere capping and canonical Wnt signaling support one another under normal conditions to maintain the intestinal stem cell niche (<xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref>; <xref ref-type="bibr" rid="bib115">Yang et al., 2017</xref>). In the setting of telomere dysfunction, this virtuous cycle becomes vicious: the resulting suppression of Wnt signaling interferes with stem cell function directly, and it also amplifies telomere dysfunction by diminishing Wnt-dependent expression of telomere maintenance factors, including the catalytic subunit of telomerase, <italic>TERT</italic>, and several of the telomere-protective shelterins. These studies demonstrated that Wnt pathway agonists (including GSK3 inhibitors, which mimic the inhibition of GSK3 by Wnts) can rescue these defects, raising the possibility that Wnt agonism could be of therapeutic benefit in DC. Given how telomere dysfunction in AT2 cells appears to drive PF, we wondered if Wnt agonism might be of benefit in PF. Wnt signaling is important for lung epithelial cell development (<xref ref-type="bibr" rid="bib28">Frank et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Goss et al., 2009</xref>; <xref ref-type="bibr" rid="bib61">Li et al., 2002</xref>; <xref ref-type="bibr" rid="bib62">Li et al., 2005</xref>; <xref ref-type="bibr" rid="bib69">Maretto et al., 2003</xref>; <xref ref-type="bibr" rid="bib77">Okubo and Hogan, 2004</xref>; <xref ref-type="bibr" rid="bib78">Ostrin et al., 2018</xref>; <xref ref-type="bibr" rid="bib94">Shu et al., 2005</xref>) and regeneration of the adult lung in response to injury (<xref ref-type="bibr" rid="bib74">Nabhan et al., 2018</xref>; <xref ref-type="bibr" rid="bib121">Zacharias et al., 2018</xref>). On the one hand, there is evidence that Wnts may drive PF; for example, they have been found to be upregulated in patients with PF (<xref ref-type="bibr" rid="bib16">Chilosi et al., 2003</xref>; <xref ref-type="bibr" rid="bib50">Königshoff et al., 2008</xref>; <xref ref-type="bibr" rid="bib51">Königshoff et al., 2009</xref>). On the other hand, when the canonical Wnt transcriptional effector β-catenin is deleted in AT2 cells, mice are sensitized to bleomcyin induced PF (<xref ref-type="bibr" rid="bib101">Tanjore et al., 2013</xref>). Wnt signaling is complex and context dependent (<xref ref-type="bibr" rid="bib113">Wiese et al., 2018</xref>), and the exact spatial, temporal, and cell-type specificity of Wnt signaling in PF remains an area of intense investigation. It is difficult to extrapolate from observational pathologic studies of fully developed PF to the potential functional impact of Wnts at earlier stages of the disease, and the large number of interacting cell types in PF lungs also makes it challenging to identify primary drivers in such studies. Furthermore, differences between mouse and human telomere biology together with the generally lower susceptibility of mice to PF make mouse modeling difficult. We therefore generated AT2 cell organoids by directed differentiation of human iPSCs (iPSC-derived AT2 [iAT2] cells) to explore how telomere dysfunction might impact their function (<xref ref-type="bibr" rid="bib38">Jacob et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Jacob et al., 2019</xref>).</p><p>By comparing iAT2s that are isogenic except for an introduced mutation in the gene most often mutated in DC, X-linked <italic>DKC1</italic>, we show that mutant iAT2 cells become senescent in concert with telomere shortening and uncapping. iAT2 cells with short, uncapped telomeres exhibit gene expression changes consistent with decreased Wnt signaling, and treatment with GSK3 inhibitors, such as CHIR99021, rescues their growth and telomere dysfunction. These findings raise the possibility that Wnt agonists may be of benefit in rescuing the stem cell and telomere defects of AT2 cells associated with PF in DC patients.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Engineering a <italic>DKC1</italic> mutation into iPS cells</title><p>To model the AT2 cells from DC patients, we engineered a well-characterized, causal DC mutation in <italic>DKC1</italic> (<italic>DKC1</italic> A386T) (<xref ref-type="bibr" rid="bib1">Agarwal et al., 2010</xref>; <xref ref-type="bibr" rid="bib11">Batista et al., 2011</xref>; <xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref>) into the BU3 <italic>NKX2.1::GFP SFTPC::TdTomato</italic> (NGST) human iPS cell line (<xref ref-type="bibr" rid="bib38">Jacob et al., 2017</xref>). We established an isogenic pair of cell lines: an introduced mutant line and a corresponding unedited wild-type (WT) line (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A-C</xref>). Both iPS lines maintained markers of pluripotency and normal karyotypes after the introduction of the <italic>DKC1</italic> A386T mutation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>).</p><p>Previous work (<xref ref-type="bibr" rid="bib1">Agarwal et al., 2010</xref>; <xref ref-type="bibr" rid="bib11">Batista et al., 2011</xref>; <xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref>) established that iPS cells with the <italic>DKC1</italic> A386T mutation exhibit decreased telomerase activity resulting in telomere shortening with passage. We confirmed that telomerase activity was reduced, and telomeres shortened with successive passages, in the BU3 NGST <italic>DKC1</italic> A386T iPS cell line when compared to its WT control (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A-C</xref>).</p></sec><sec id="s2-2"><title>iAT2 cells with short telomeres fail to form alveolospheres and grow in size</title><p>We next differentiated these paired iPS cell lines into iAT2 cells using the protocol developed by Jacob et al. (see <xref ref-type="fig" rid="fig1">Figure 1A</xref> for differentiation strategy, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A, B</xref> for representative sorting strategies). Using iPSCs 35 passages after the introduction of the mutation yielded iAT2s that initially grew in a similar fashion to WT, but which over time developed a growth defect characterized by lower alveolosphere formation efficiency as well as smaller alveolospheres. The phenotype became apparent by 50 days of culture (D50) and was dramatic by D70 (<xref ref-type="fig" rid="fig1">Figure 1A–C</xref>). In contrast, using iPSCs only five passages after the introduction of the mutation yielded iAT2s with less dramatic defects in alveolosphere growth and size at D70 (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A-C</xref>). These data indicate that the defects observed were due to progressive telomere shortening after introducing the <italic>DKC1</italic> mutation, and not the immediate effects of telomerase deficiency (or other potential deficiencies) caused by the <italic>DKC1</italic> A386T mutation per se.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Dyskeratosis congenita induced pluripotent stem cell (iPSC)-derived type II alveolar epithelial cells (iAT2s) fail to form alveolospheres with successive passaging.</title><p>(<bold>A</bold>) Differentiation protocol used to probe the effects of the <italic>DKC1</italic> A386T mutation on iAT2 cells. D.E., definitive endoderm specification; Ant., anteriorization. (<bold>B</bold>) Representative images of differentiating wild type and <italic>DKC1</italic> A386T mutant bearing iAT2 alveolospheres (scale bars, 100 µm as indicated for iPS and <italic>NKX2.1+</italic> progenitors; 1 mm for all alveolosphere images). (<bold>C</bold>) Quantifications of alveolosphere area and formation efficiency on D70 (n = 4; ** p&lt;0.01, **** p&lt;0.0001, and Student’s t-test). (<bold>D</bold>) Quantification of the percentage <italic>SFTPC+</italic> cells and the number of <italic>SFTPC+</italic> cells produced with passage of the iAT2 cells shows <italic>DKC1 A386T</italic> iAT2 alveolospheres accumulate fewer <italic>SFTPC+</italic> cells (n = 4; ** p&lt;0.01, and Student’s t-test). (<bold>E</bold>) RNA-seq of sorted <italic>SFTPC+</italic> iAT2 cells at different passages shows AT2 cell genes are not grossly affected by the <italic>DKC1</italic> A386T mutation (n = 4, W = wild type, M = mutant).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source Data for <xref ref-type="fig" rid="fig1">Figure 1C-E</xref>.</title><p><xref ref-type="fig" rid="fig1">Figure 1C</xref>-SourceData-FormationEfficiency&amp;OrganoidArea.pzfx – Raw counts of organoid counts normalized to number of cells input to calculate formation efficiency as well as area measurements along with statistical tests. <xref ref-type="fig" rid="fig1">Figure 1D</xref>-SourceData-SFTPC%&amp;SFTPCCumYield.pzfx – Percentage SFTPC+ along the differentiation of the induced pluripotent stem cell-derived type II alveolar epithelial cells (iAT2s) from sort flow plots along with cumulative yield of surfactant protein C calculated as the number of SFTPC+ cells produced over the experiment over time. <xref ref-type="fig" rid="fig1">Figure 1E</xref>-SourceData-AT2Markers.pzfx – Raw counts from RNA-seq of iAT2s over the differentiation specifically looking at AT2 markers.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Introduction of the <italic>DKC1 A386T</italic> mutation into the BU3 <italic>NKX2.1::GFP SFTPC::TdTomato</italic> (NGST) induced pluripotent stem (iPS) cell line.</title><p>(<bold>A</bold>) CRISPR-based editing strategy for introducing the <italic>DKC1 A386T</italic> mutation into the BU3 NSGT iPS cell line. (<bold>B</bold>) Genotyping by RFLP of <italic>DKC1</italic> A386T clonal cell lines and their wild-type (WT) counterparts that also were exposed to the CRISPR reagents using the introduced NdeI site. (<bold>C</bold>) Sanger sequence verification of the introduction of the mutation yielding 1156G&gt;A. Note the WT sequence is marked in red. (<bold>D</bold>) Paired iPS cell clones maintain high expression of NANOG, a marker of pluripotency (scale bars, 100 µm). (<bold>E</bold>) Paired iPS cell clones show normal karyotypes after the introduction of the <italic>DKC1</italic> A386T mutation.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B,C and E</xref>.</title><p><xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>-SourceData-2020-07-17-FigureS1-NdeIGeno-CroppingLabeled.tiff – Genotyping agarose gel showing area that was cropped for the <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>-SourceData-2020-07-17-FigureS1-NdeIGeno.tiff – Raw agarose gel image for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>-SourceData-DKC1A386T-34.2DA9_B05_045.ab1 – Sanger sequencing file for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref> of BU3 NGST DKC1 A386T mutant iPS line. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>-SourceData-WT-33.3EF6_A05_047.ab1 – Sanger sequencing file for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref> of BU3 NGST wild type (WT) control iPS line. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>-SourceData-DKC1A386T-KaryotypeImageCLG-35870.pdf – Image of a representative karyotype of BU3 NGST DKC1 A386T iPS line. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>-SourceData-DKC1A386T-REPORTCLG-35870.pdf – Report of karyotype analysis for BU3 NGST DKC1 A386T iPS line. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>-SourceData-WT-KaryotypeImageCLG-35869.pdf – Image of a representative karyotype of BU3 NGST WT control iPS line. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>-SourceData-WT-REPORTCLG-35869.pdf – Report of karyotype analysis for BU3 NGST WT control iPS line.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title><italic>DKC1</italic> A386T induced pluripotent stem (iPS) cells show decreased telomerase activity and telomeres shorten with passage.</title><p>(<bold>A</bold>) Quantitative telomeric repeat amplification protocol assay for telomerase activity in iPS cells shows a reduction in relative telomerase activity in <italic>DKC1</italic> A386T introduced line (n = 3). AG04646 is an iPSC line derived from a dyskeratosis congenita patient with the A386T mutation, and the wild-type (WT) line is an unedited clone derived along with the A386T-introduced clone from the BU3 parental iPSC line. (<bold>B</bold>) Telomeric repeat amplification protocol assay for telomerase activity in iPS cells using a fivefold dilution series of the cellular extracts shows a reduction in relative telomerase activity in <italic>DKC1</italic> A386T introduced lines. (<bold>C</bold>) Terminal restriction fragment telomere length analyses in the WT and <italic>DKC1 A386T</italic> paired iPS cells compared to the parental iPS line (BU3 <italic>NGST</italic>) and the patient derived iPS line (AG04646). Above each lane is the number of passages from the introduction of the mutation.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A-C</xref>.</title><p><xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>-SourceData-qTRAPiPS-2018-09-06-007_qTRAP_BU3_Paired_Cell_Line.xlsx – Raw Cq (quantification cycle) data for quantitative telomeric repeat amplification protocol of different iPS lines. <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>-SourceData-iPSWTDKC1A386TTRAP-2020-07-24-102Intense.tiff – Uncropped image of telomeric repeat amplification protocol (TRAP) gel for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>. <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>-SourceData-2019-03-29-055TRFBU3A386T_60_60_60-Cropped.tif – Uncropped image of TRAP gel for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref> showing where cropping occurred. <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>-SourceData-2019-03-29-055TRFBU3A386T_60_60_60.tif – Uncropped raw image of Terminal restriction fragment (TRF blot for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>-SourceData-2019-03-29-055TRFBU3A386T_60_60_60-Cropped.tiff – Uncropped raw image of TRF blot for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref> showing how cropping removed the central ladder to aid in observation of iPS lines.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig1-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Representative sorting strategies for <italic>NKX2.1+</italic> progenitors and <italic>SFTPC</italic>+ induced pluripotent stem cell-derived type II alveolar epithelial (iAT2) cells.</title><p>(<bold>A</bold>) Representative sorting strategy for <italic>NKX2.1+</italic> progenitors. (<bold>B</bold>) Representative sorting strategy for <italic>SFTPC+</italic> cells from iAT2 alveolospheres.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Differentiation of induced pluripotent stem cell (iPSC)-derived type II alveolar epithelial cell (iAT2) alveolospheres from early passage iPS cells yields no growth defect.</title><p>(<bold>A</bold>) Differentiation protocol used to probe the effects of the <italic>DKC1 A386T</italic> mutation on iAT2 cells. D.E., definitive endoderm specification; Ant., anteriorization. (<bold>B</bold>) Representative images of differentiating wild type (WT) and <italic>DKC1</italic> A386T mutant bearing iAT2 alveolospheres derived from iPS cells that have undergone five passages after introduction of the mutation. (scale bars, 1 mm). (<bold>C</bold>) Quantifications of the formation efficiency on D70 of iAT2 alveolospheres derived from iPS cells that have undergone five passages after introduction of the mutation (n=3, p=0.81, and Student’s t-test).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig1-figsupp4-v2.tif"/></fig></fig-group><p>Surfactant protein C (SFTPC) is a highly specific marker of AT2 cells (<xref ref-type="bibr" rid="bib42">Kalina et al., 1992</xref>), and the yield of <italic>SFTPC::TdTomato+</italic> (<italic>SFTPC+</italic>) cells was reduced significantly at D70 in <italic>DKC1</italic> mutant cultures, while the percentage of <italic>SFTPC+</italic> cells generated at each time point was not different, suggesting that there is a defect in AT2 cell proliferation or survival (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Sorted <italic>SFTPC+</italic> cells from iAT2 cell alveolospheres maintained expression of multiple AT2 specific genes suggesting that the introduced mutation did not affect lineage specification (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Thus, DC iPS cells can generate iAT2 cell alveolospheres; however, these alveolospheres lose the capacity to self-renew with successive passaging.</p></sec><sec id="s2-3"><title>DC iAT2 cells derived from iPS cells 35 passages after introduction of the mutation develop hallmarks of senescence at late passage (D70)</title><p>To better understand the AT2 cell defects, we further compared the WT and mutant iAT2 alveolospheres at different passages. RNA-seq-based gene expression analyses over successive passages of sorted <italic>SFTPC+</italic> cells from iAT2 alveolospheres showed decreases in proliferation markers (<italic>MKI67</italic> and <italic>MCM2</italic>) as well as an increase in expression of the cell cycle inhibitor <italic>CDKN1A</italic> (p21), and these changes were most pronounced in mutant alveolospheres (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Immunofluorescence microscopy based analyses of D70 mutant iAT2 alveolospheres showed an increase in DNA damage marked by 53BP1 foci (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and an increased fraction of cells expressing p21 protein (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), but no increase in apoptosis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A-C</xref>). Measuring telomere length using qPCR, DC, and WT iAT2 cells showed no significant change in average telomere length with passage, although average telomere lengths in mutants trended shorter than in WT (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). However, measuring telomere lengths using TeSLA (<xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref>), which is more sensitive for the detection of short telomeres than most other techniques, revealed that DC iAT2 cells had a preponderance of short telomeres at D70 (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>). Consistent with this, DC iAT2 alveolospheres showed an increased number of telomere dysfunction induced foci (TIFs), a hallmark of uncapped telomeres (i.e., telomeres that signal DNA damage responses and cell cycle checkpoint arrest <xref ref-type="bibr" rid="bib100">Takai et al., 2003</xref>; <xref ref-type="fig" rid="fig2">Figure 2D</xref>). These findings indicate that the short and uncapped telomeres that accumulate with passage of DC iAT2 cells lead them to senesce.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Dyskeratosis congenita induced pluripotent stem cell-derived type II alveolar epithelial cells (iAT2s) 35 passages after introduction of the mutation at D70 show hallmarks of senescence.</title><p>(<bold>A</bold>) Gene expression profiling of iAT2 cells at D28 and D50 shows no difference between wild type and <italic>DKC1</italic> A386T in expression of markers of proliferation and a cell cycle inhibitor, while at D70 cells, there is a significant decrease in <italic>MCM2</italic> and <italic>MKI67</italic> as well as a significant increase in <italic>CDKN1A</italic> (<bold>p21</bold>) (n = 4, **** p&lt;0.0001, DEseq2 pairwise contrast statistics). (<bold>B</bold>) At D70, <italic>DKC1</italic> A386T mutant iAT2 cells have a higher fraction of cells with 53BP1 foci (n = 4, * p&lt;0.05, and Student’s t-test; scale bars, 10 µm; insets highlight cells with 53BP1 foci as noted by the white arrowheads). (<bold>C</bold>) At D70, <italic>DKC1</italic> A386T mutant iAT2s have a higher fraction of cells positive for p21 (n = 4, * p&lt;0.05, and student’s t-test; scale bars, 10 µm). (<bold>D</bold>) At D70, <italic>DKC1</italic> A386T mutant iAT2s have a higher fraction of cells with telomere dysfunction induced foci (TIFs) (n = 4, * p&lt;0.05, and Student’s t-test; scale bars, 10 µm; insets highlight cells with TIFs, each one noted by a white arrowhead). (<bold>E</bold>) Representative TeSLA of <italic>DKC1</italic> A386T iAT2 alveolospheres shows telomeres shorten with passage. (<bold>F</bold>) Quantification of <italic>DKC1</italic> A386T iAT2 cell telomere lengths shows a preponderance of short telomeres appears as the iAT2 cells approach D70, red colored data points highlight telomeres under the 1.6 kb threshold (n = 2, ‘shortest 20%’ reports the 20th percentile of telomere length, in Kb).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title><p><xref ref-type="fig" rid="fig2">Figure 2A</xref>-SourceData-iAT2-SenescentGeneExpression.pzfx – Raw counts from RNA-seq of induced pluripotent stem cell-derived type II alveolar epithelial cells over the differentiation specifically looking at specific senescence related genes.</p><p><xref ref-type="fig" rid="fig2">Figure 2B</xref>-SourceData-53BP1PositiveCounts.pzfx – Raw counts of 53BP1 positive cells along with statistics. <xref ref-type="fig" rid="fig2">Figure 2C</xref>-SourceData-p21PositiveCounts.pzfx – Raw counts of p21 positive cells along with statistics. <xref ref-type="fig" rid="fig2">Figure 2D</xref>-SourceData-TIFPhenotype.pzfx – Raw counts of telomere dysfunction induced foci positive cells along with statistics. <xref ref-type="fig" rid="fig2">Figure 2E,F</xref>-SourceData-2020-08-31-TeSLABlotMerged-Cropped.tiff – Uncropped raw image of TeSLA blot along the differentiation showing where the crop was placed for <xref ref-type="fig" rid="fig2">Figure 2E</xref>. This is the same blot as used in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>. <xref ref-type="fig" rid="fig2">Figure 2E,F</xref>-SourceData-2020-08-31-TeSLABlotMerged.tiff – Uncropped raw image of TeSLA blot along the differentiation showing where the crop was placed for <xref ref-type="fig" rid="fig2">Figure 2E</xref>. This is the same blot as used in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>. <xref ref-type="fig" rid="fig2">Figure 2E,F</xref>-SourceData-TeSLADKC1A386TAlongDiff.pzfx – Raw counts from TeSLA quant software analysis of cropped blot looking at telomere length along the differentiation along with statistical analysis.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Dyskeratosis congenita induced pluripotent stem cell-derived type II alveolar epithelial cells (iAT2s) 35 passages after introduction of the mutation at D70 do not show an increase in apoptosis.</title><p>(<bold>A</bold>) Representative images and quantification of CC3 staining at D70 show no significant difference between wild type (WT) and <italic>DKC1</italic> A386T mutant iAT2 alveolospheres. (<bold>B</bold>) Quantification of CC3+ cells in D70 iAT2 alveolospheres (n = 4, no difference, p=0.96, student’s t-test; scale bars, 10 µm). (<bold>C</bold>) CC3 positive control: day 0 postnatal lung from a mouse exposed to hyperoxia (panel on right) served as a positive control for CC3 staining.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>.</title><p><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>-SourceData-CC3Counts.pzfx – Raw counts of CC3 positive cells along with statistics.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Telomere qPCR reveals a trend toward shorter average telomere lengths in dyskeratosis congenita (DC) induced pluripotent stem cell-derived type II alveolar epithelial (iAT2) cells.</title><p>(<bold>A</bold>) Average telomere length as measured by telomere qPCR of wild type (WT) and DC iAT2 cells with passage (n = 2, p-values listed on the figure, Student’s t-test).</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title><p><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>-SourceData-TelomereqPCR.pzfx – Raw Cq values from telomere qPCR for measuring average telomere lengths.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig2-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig2-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>RNA-seq reveals pathways differentially expressed in DC iAT2 cells, including those related to Wnt signaling</title><p>To further understand changes in the DC iAT2 cells, we more broadly evaluated RNA-seq-based gene expression changes of sorted <italic>SFTPC</italic>+ iAT2 cells. (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We found very few significantly differentially expressed genes when comparing WT and mutant cells at D28 and D50, but a large number of differentially expressed genes at D70 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), arguing that the gene expression changes seen at D70 are likely driven by uncapped telomeres. Gene set enrichment analyses (GSEA) revealed an upregulation of the DNA damage response, the unfolded protein response (UPR), mitochondrial related functions (oxidative phosphorylation, the respiratory electron chain), a downregulation of hypoxia related signaling, and hedgehog signaling along with other changes (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for a full list). Ingenuity pathway analysis (IPA) revealed similar changes as well as defects in multiple pathways controlled by inflammatory cytokines like IL1β, IL6, IL17, and others (see <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for the full lists). We found a marked upregulation in DC iAT2 cells of many pathways associated with PF (see <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for curated list of PF related pathways, see <xref ref-type="supplementary-material" rid="supp1 supp2">Supplementary files 1 and 2</xref> for the unedited analyses). These included the UPR (<xref ref-type="bibr" rid="bib57">Lawson et al., 2008</xref>; <xref ref-type="bibr" rid="bib73">Mulugeta et al., 2005</xref>), thyroid hormone metabolism (<xref ref-type="bibr" rid="bib119">Yu et al., 2018</xref>), p53 signaling (<xref ref-type="bibr" rid="bib93">Shetty et al., 2017</xref>), mitochondrial dysfunction and mitophagy (<xref ref-type="bibr" rid="bib18">Chung et al., 2019</xref>; <xref ref-type="bibr" rid="bib119">Yu et al., 2018</xref>), and caveolin function (<xref ref-type="bibr" rid="bib110">Wang et al., 2006</xref>). This analysis also showed an upregulation of non-canonical Wnt signaling (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), which correlated with a significant upregulation in <italic>WNT5A</italic> and <italic>WNT11</italic>, known non-canonical Wnt ligands (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Furthermore, almost every <italic>FZD</italic> gene, encoding co-receptors for canonical Wnt signaling, was downregulated in DC iAT2 cells (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Also, GSEA found genes with TCF7 targets in their promoters are downregulated in DC iAT2 cells at D70 (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). IPA of master regulators at D70 revealed a decrease in genes controlled by lithium chloride (which can potentiate Wnt signaling by inhibiting GSK3) and TCF7 along with an upregulation of genes usually stimulated by Wnt pathway inhibitors (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). GSEA also revealed a significant downregulation of targets of <italic>miR34a</italic>, a miRNA that we previously demonstrated negatively regulates many components of the Wnt pathway in response to uncapped telomeres (<xref ref-type="fig" rid="fig3">Figure 3H</xref>; <xref ref-type="bibr" rid="bib115">Yang et al., 2017</xref>). The genes encoding four of the six shelterins, proteins that bind and help maintain normal telomere function, are direct targets of the canonical Wnt transcriptional effector β-catenin, and two of these, <italic>TINF2</italic> and <italic>POT1,</italic> were downregulated in D70 DC iAT2 cells, which may contribute to telomere uncapping beyond simple telomere shortening (<xref ref-type="fig" rid="fig3">Figure 3I</xref>; <xref ref-type="bibr" rid="bib115">Yang et al., 2017</xref>). These genes were confirmed to be downregulated by ddPCR, and furthermore, DC iAT2 cells expressed lower levels of both <italic>TERT</italic> and <italic>TERC</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). These data indicate that Wnt signaling in AT2 cells is greatly affected by shortened telomeres and that non-canonical Wnt signaling may be elevated while canonical (β-catenin-dependent) signaling may be diminished.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>RNA-seq of passaged induced pluripotent stem cell-derived type II alveolar epithelial (iAT2) cells reveals a time dependent change in Wnt signaling.</title><p>(<bold>A</bold>) A schematic to show how cells were prepared for RNA-seq. (<bold>B</bold>) Volcano plots at D28, D50, and D70 show how the number of differentially expressed genes increases at D70. (<bold>C</bold>) Gene set enrichment analyses (GSEA) at D70 comparing <italic>DKC1</italic> A386T iAT2 cells reveal an upregulation of non-canonical Wnt signaling and the planar cell polarity (PCP) pathway. (<bold>D</bold>) RNA-seq analysis shows upregulation of <italic>WNT5A</italic> and <italic>WNT11</italic>, non-canonical WNTs associated with pulmonary fibrosis (* p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001, **** p&lt;0.0001, DEseq2 pairwise contrast statistics). (<bold>E</bold>) RNA-seq analysis shows broad downregulation of many <italic>FZD</italic> receptors (* p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001, **** p&lt;0.0001, DEseq2 pairwise contrast statistics). (<bold>F</bold>) GSEA at D70 comparing <italic>DKC1</italic> A386T iAT2 cells reveals a downregulation of genes with <italic>TCF7</italic> bindings sites in their promoters. (<bold>G</bold>) Ingenuity pathway analysis reveals master regulators at D70 including downregulation of regulation associated with lithium chloride and <italic>TCF7</italic>, and upregulation of regulation associated with multiple Wnt inhibitors. (<bold>H</bold>) GSEA at D70 comparing <italic>DKC1</italic> A386T iAT2 cells reveals a downregulation of genes with <italic>miR34A</italic> binding sites. <italic>TINF2</italic> and <italic>POT1</italic> are downregulated in <italic>DKC1</italic> A386T iAT2 cells at D70 (* p&lt;0.05, ** p&lt;0.01).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>ddPCR demonstrates key shelterin and telomerase related genes are downregulated in dyskeratosis congenita (DC) induced pluripotent stem cell-derived type II alveolar epithelial (iAT2) cells.</title><p>ddPCR of <italic>TINF2</italic>, <italic>POT1</italic>, <italic>TERT,</italic> and <italic>TERC</italic> (normalized to <italic>ACTB</italic>) showing significant decreases in the expression of these genes in DC iAT2 cells (n = 2). The organoids used were equivalent to those tested in the main panels of <xref ref-type="fig" rid="fig3">Figure 3</xref> except that they were cultured for an additional 7 days in K + DCI + TZV.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title><p><xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>-SourceData-2022-01-27-112-ddPCRWTMut.pzfx – Raw data of ddPCR of WT and DKC1 A386T iAT2s at D77.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>GSK3 inhibitors rescue the growth of DC iAT2 alveolospheres</title><p>Given our previous work showing that GSK3 inhibition reverses telomere dysfunction and associated defects in intestinal models of DC (<xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref>; <xref ref-type="bibr" rid="bib115">Yang et al., 2017</xref>), we attempted to rescue the DC iAT2 alveolosphere formation defect by treatment with CHIR99021, a well-characterized GSK3 inhibitor, which thus stabilizes β-catenin and upregulates canonical Wnt target genes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). CHIR99021 partially rescued the alveolosphere growth defect of iAT2 cells in a dose dependent fashion (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>). Furthermore, if alveolospheres were cultured continuously prior to D70 with CHIR99021, this prevented the growth defect from emerging (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-B</xref>). We also tested another GSK3 inhibitor, CHIR98014, which similarly rescued growth of the mutant iAT2 cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A-B</xref>). These findings suggest that GSK3 inhibition rescued the growth of DC iAT2 alveolospheres.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CHIR99021 rescues growth and telomere defects in dyskeratosis congentia (DC) induced pluripotent stem cell-derived type II alveolar epithelial (iAT2) cell alveolospheres.</title><p>(<bold>A</bold>) Differentiation protocol used to test how CHIR99021 affects growth of DC iAT2s. (<bold>B</bold>) Representative images of differentiating wild type (WT) and <italic>DKC1</italic> A386T mutant bearing cells with increasing amounts of CHIR99021 (scale bars, 1 mm for all alveolosphere images). (<bold>C</bold>) Quantifications of alveolosphere formation efficiency after treatment with differing concentrations of CHIR99021 (n = 4, * p&lt;0.05, **** p&lt;0.0001, Student’s t-test). (<bold>D</bold>) When D70 alveolospheres are cultured with 3 µM CHIR99021, <italic>DKC1</italic> A386T mutant iAT2 cells have a lower fraction of cells with 53 BP1 foci. Note, data for no CHIR99021 bars are from <xref ref-type="fig" rid="fig2">Figure 2</xref> (n = 3, * p&lt;0.05, Student’s t-test; scale bars, 10 µm). (<bold>E</bold>) When D70 alveolospheres are cultured with 3 µM CHIR99021, <italic>DKC1</italic> A386T mutant iAT2 cells have a lower fraction of p21 positive cells. Note, data for no CHIR99021 bars are from <xref ref-type="fig" rid="fig2">Figure 2</xref> (n = 3, * p&lt;0.05, Student’s t-test; scale bars, 10 µm). (<bold>F</bold>) When D70 alveolospheres are cultured with 3 µM CHIR99021, <italic>DKC1</italic> A386T mutant iAT2 cells have a lower fraction of telomere dysfunction induced foci (TIF) positive cells. Note, data for no CHIR99021 bars are from <xref ref-type="fig" rid="fig2">Figure 2</xref> (n = 3, * p&lt;0.05, Student’s t-test; scale bars, 10 µm; insets highlight cells with TIFs, each one noted by the white arrowheads). (<bold>G</bold>) Telomeric repeat amplification protocol assay for telomerase activity in iAT2 cells using fivefold extract dilutions (n = 3).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4C-G</xref>.</title><p><xref ref-type="fig" rid="fig4">Figure 4C</xref>-SourceData-OrganoidFormationEfficiency.pzfx – Raw counts of organoid counts normalized to number of cells input to calculate formation efficiency along with statistical tests. <xref ref-type="fig" rid="fig4">Figure 4D</xref>-SourceData-53BP1Rescue.pzfx – Raw counts of 53BP1 positive cells after treatment with CHIR99021 along with statistics. <xref ref-type="fig" rid="fig4">Figure 4E</xref>-SourceData-p21Rescue.pzfx – Raw counts of p21 positive cells after treatment with CHIR99021 along with statistics. <xref ref-type="fig" rid="fig4">Figure 4F</xref>-SourceData-TIFRescue.pzfx – Raw counts of telomere dysfunction induced foci positive cells after treatment with CHIR99021 along with statistics.<xref ref-type="fig" rid="fig4">Figure 4G</xref>-SourceData-2021-05-04-109-CK-Cropped.tiff – Raw blot of telomeric repeat amplification protocol (TRAP) assay of iPSC-derived type II alveolar epithelial (iAT2) cells treated with CHIR99021 showing area that was cropped. <xref ref-type="fig" rid="fig4">Figure 4G</xref>-SourceData-2021-05-04-109-CK.tif – Raw blot of TRAP assay of iAT2 cells treated with CHIR99021. <xref ref-type="fig" rid="fig4">Figure 4G</xref>-SourceData-2021-05-04-109-K-Cropped.tiff – Raw blot of TRAP assay of untreated iAT2 showing area that was cropped. <xref ref-type="fig" rid="fig4">Figure 4G</xref>-SourceData-2021-05-04-109-K.tif – Raw blot of TRAP assay of untreated iAT2. <xref ref-type="fig" rid="fig4">Figure 4G</xref>-SourceData-2021-05-04-109-QuantificationTRAP.xlsx – Quantifications of TRAP assay in <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The growth defect in dyskeratosis congenita (DC) induced pluripotent stem cell-derived type II alveolar epithelial (iAT2) cells is rescued by continuous treatment of CHIR99021 from D28 to D70 but not if withdrawn at D56.</title><p>(<bold>A</bold>) Differentiation protocol used to test how withdrawal of CHIR99021 at D56 affects growth of DC iAT2s at D70. (<bold>B</bold>) Representative images of iAT2 alveolospheres at D70 when CHIR99021 (present up to D56) was either continued or removed after D56 and the cells analyzed at D70. If CHIR99021 is maintained, the growth defect is suppressed, while if CHIR99021 is removed the growth defect emerges (scale bars, 1 mm).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>CHIR98014 can rescue dyskeratosis congenita (DC) induced pluripotent stem cell-derived type II alveolar epithelial (iAT2) cell growth.</title><p>(<bold>A</bold>) Differentiation protocol used to test whether CHIR98014 can affect the growth of DC iAT2s at D70. (<bold>B</bold>) Rescue of DC iAT2 alveolosphere growth with CHIR98014. These alveolospheres grew from cells plated at 400 cells/µL (scale bars, 1 mm).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>TeSLA revealed a modest increase in average telomere length but no apparent decrease in the frequency of shortest detectable telomeres.</title><p>(<bold>A</bold>) Differentiation protocol used to test how CHIR99021 affects growth of dyakeratosis congenita induced pluripotent stem cell-derived type II alveolar epithelial cells (iAT2s), same as in <xref ref-type="fig" rid="fig4">Figure 4</xref>. (<bold>B</bold>) TeSLA of <italic>DKC1</italic> A386T iAT2 alveolospheres treated with 3 µM CHIR99021 as per differentiation protocol in A. (<bold>C</bold>) Quantification of TeSLA blot of <italic>DKC1</italic> A386T iAT2 alveolospheres (n = 1, ‘shortest 20%’ reports the 20th percentile of telomere length, in Kb).</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</title><p><xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>-SourceData-2020-08-31-MergedTeslaDKC1A386T-Cropped – Uncropped raw image of TeSLA blot when DKC1 A386T iPSC-derived type II alveolar epithelial cells (iAT2s) were treated with CHIR99021 showing where the crop was placed for <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>. This is the same blot as used in <xref ref-type="fig" rid="fig2">Figure 2E</xref>. <xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>-SourceData-2020-08-31-MergedTeslaDKC1A386T – Uncropped raw image of TeSLA blot when DKC1 A386T iAT2s were treated with CHIR99021. This is the same blot as used in <xref ref-type="fig" rid="fig2">Figure 2E</xref>. <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3C</xref>-SourceData-DKC1A386TTesLARescue – Quantification of TeSLA using TeSLA quant software for DKC1 A386T mutant cells treated with CHIR99021.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64430-fig4-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64430-fig4-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>CHIR99021 downregulates senescence markers and resolves TIFs in DC iAT2 alveolospheres</title><p>We ultimately investigated how CHIR99021 affects the telomere status of DC iAT2s. CHIR treated iAT2 cells showed fewer cells with 53BP1 foci, fewer p21+ cells, and fewer TIF+ cells (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>). TeSLA revealed a modest increase in average telomere length but no apparent decrease in the frequency of shortest detectable telomeres (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A-C</xref>). iAT2 cell telomerase activity was restored in mutant cells treated with CHIR99021 to levels similar to those seen in WT cells (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Together, these data argue that GSK3 inhibition not only rescues the growth of DC iAT2 cells, but it also rescues telomere defects, most likely through upregulation of telomerase activity that could extend telomeres that are shorter than those that can be detected by TeSLA; it is also possible that telomerase is contributing to telomere capping via lengthening-independent mechanisms (<xref ref-type="bibr" rid="bib82">Perera et al., 2019</xref>). Of note, withdrawal of CHIR99021 during only 14 days prior to D70 was sufficient to elicit the growth defect (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-B</xref>), consistent with an only modest increase in telomere length associated with the increased telomerase activity.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We used isogenic human iPS cell lines to generate DC mutant iAT2 cells with shortened telomeres to interrogate how telomere dysfunction can affect AT2 cell function. We found that shortened and uncapped telomeres are associated with a defect in alveolosphere formation by iAT2 cells. This defect is characterized by senescent iAT2 cells that upregulate many pathways associated with PF including the UPR, mitochondrial biogenesis and function, thyroid hormone signaling, and p53 signaling. DC mutant iAT2 cells also suppress canonical Wnt signaling, and consistent with this, GSK3 inhibition rescues telomerase activity, telomere capping, and alveolosphere formation. This system provides a new preclinical model to better understand PF pathogenesis and how potential new PF therapeutics affect AT2 cell function in the context of telomere dysfunction.</p><p>Wnt signaling is complex and can be broken down into two major categories: β-catenin dependent (canonical) signaling and β-catenin independent (non-canonical) signaling. These distinctions can also be blurred as evidenced by studies that show how non-canonical ligands, such as <italic>WNT5A</italic>, can activate both arms of Wnt signaling (<xref ref-type="bibr" rid="bib108">van Amerongen et al., 2012</xref>; <xref ref-type="bibr" rid="bib72">Mikels and Nusse, 2006</xref>). These complexities therefore make the conflicting reports about whether β-catenin dependent Wnt signaling is of benefit (<xref ref-type="bibr" rid="bib101">Tanjore et al., 2013</xref>) or of harm in PF (<xref ref-type="bibr" rid="bib23">Douglas et al., 2006</xref>; <xref ref-type="bibr" rid="bib34">Henderson et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Kim et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Königshoff et al., 2008</xref>; <xref ref-type="bibr" rid="bib71">McDonough et al., 2019</xref>) unsurprising. Given the heterogeneity of the disease both in space and time and the context dependence of Wnt signaling, these studies can often only capture a snapshot of the fibrotic response. Furthermore, there are clear differences between mice and humans with regard to telomere and lung biology (<xref ref-type="bibr" rid="bib10">Basil and Morrisey, 2020</xref>; <xref ref-type="bibr" rid="bib29">Gomes et al., 2011</xref>). These limitations highlight the need for human models capable of assessing the spatial, temporal, and cell type specific properties of Wnt signaling in PF pathogenesis.</p><p>Our study also provides evidence of upregulation of β-catenin-independent signaling in DC iAT2 cells and that re-activating β-catenin dependent Wnt signaling using GSK3 inhibitors might provide support for AT2 cell proliferation in the context of telomere dysfunction. It is tempting to extrapolate from other models of lung disease to understand how the activity of the β-catenin dependent Wnt pathway might be of benefit in PF. β-catenin dependent Wnt signaling improved regeneration and survival in a model of emphysema (<xref ref-type="bibr" rid="bib48">Kneidinger et al., 2011</xref>), and inhibition of <italic>WNT5A</italic>, and thus presumably some component of β-catenin independent Wnt signaling, improved repair in a model of COPD (<xref ref-type="bibr" rid="bib7">Baarsma et al., 2017</xref>). Our work, consistent with previous studies, argues that β-catenin dependent Wnt signaling supports AT2 cell telomere capping and proliferation, which may be of benefit during regeneration and repair (<xref ref-type="bibr" rid="bib74">Nabhan et al., 2018</xref>; <xref ref-type="bibr" rid="bib105">Uhl et al., 2015</xref>; <xref ref-type="bibr" rid="bib121">Zacharias et al., 2018</xref>).</p><p>Our previous work uncovered a positive feedback loop between Wnt signaling and telomeres in the intestine (<xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref>; <xref ref-type="bibr" rid="bib115">Yang et al., 2017</xref>). Here, we show that aspects of the Wnt-telomere feedback loop appear to be at play in AT2 cells (<xref ref-type="bibr" rid="bib27">Fernandez and Johnson, 2018</xref>), arguing that this connection between Wnt and telomeres is present not just in proliferative tissues such as the intestine, but also in lung cells, which are normally quiescent but proliferate in response to injury. Previous work highlighted the importance of telomerase during alveolar regeneration (<xref ref-type="bibr" rid="bib24">Driscoll et al., 2000</xref>; <xref ref-type="bibr" rid="bib59">Lee et al., 2009</xref>). Furthermore, given previous demonstrations that Wnt can stimulate, directly or indirectly, <italic>TERT</italic> and <italic>TERC</italic> expression as well as telomerase activity in several cell types (<xref ref-type="bibr" rid="bib8">Baena-Del Valle et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Hoffmeyer et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Jaitner et al., 2012</xref>; <xref ref-type="bibr" rid="bib122">Zhang et al., 2012</xref>), we anticipated and were able to demonstrate (i) that <italic>TERT</italic> and <italic>TERC</italic> transcripts are reduced in senescent iAT2 cells and (ii) that GSK3 inhibition can restore telomerase activity in this context. Of note, CHIR99021 is known to induce proliferation in a wide variety of cell types (<xref ref-type="bibr" rid="bib36">Hesselbarth et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Jacob et al., 2017</xref>), which likely contributes to the growth stimulation observed in both WT and <italic>DKC1</italic> mutant iAT2s shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. This raises the possibility that GSK3 inhibition has additional effects independent of telomeres. We also note that the effects of CHIR99021 could differ in some ways from canonical Wnt signaling, by impacting targets other than GSK3 or by differentially affecting the numerous pathways that are downstream of GSK3. However, the Wnt-related transcriptional changes in the mutant iAT2s, the high selectivity of CHIR99021 for GSK3 and its common use as a replacement for Wnt ligands in cell culture differentiation protocols, along with the fact that two different GSK3 inhibitors rescued growth of the mutant iAT2s suggest that the rescue provided by CHIR99021 is indeed related to GSK3 and Wnt (<xref ref-type="bibr" rid="bib5">An et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Loh et al., 2016</xref>; <xref ref-type="bibr" rid="bib79">Pagliuca et al., 2014</xref>; <xref ref-type="bibr" rid="bib87">Rezania et al., 2014</xref>; <xref ref-type="bibr" rid="bib89">Ring et al., 2003</xref>; <xref ref-type="bibr" rid="bib103">Teo et al., 2014</xref>).</p><p><italic>DKC1</italic> mutant iAT2 cells displayed a senescent phenotype that included upregulation of the p21 cyclin-dependent kinase inhibitor. Recent observations have revealed similar p21 upregulation in the AT2 cells of human PF lungs and have also demonstrated a causal role for p21 in driving experimental PF in mice (<xref ref-type="bibr" rid="bib60">Lee et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Lv et al., 2022</xref>). Senescence of the mutant iAT2 cells manifested only after serial passaging and telomere shortening, demonstrating that the senescence is not a direct result of <italic>DKC1</italic> mutation per se. The senescence-associated growth defect emerged gradually, becoming more pronounced at later passages. Similarly gradual onset of telomere-driven senescence has been observed in other settings and has been attributed to (i) the stochastic nature of telomere shortening (causing some cells in a population to senesce prior to others) and (ii) graded increases in DNA damage responses in proportion to the extent of telomere shortening (<xref ref-type="bibr" rid="bib14">Cesare et al., 2009</xref>; <xref ref-type="bibr" rid="bib15">Cesare et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Kaul et al., 2011</xref>; <xref ref-type="bibr" rid="bib70">Martin-Ruiz et al., 2004</xref>; <xref ref-type="bibr" rid="bib91">Ruis and Boulton, 2021</xref>; <xref ref-type="bibr" rid="bib99">Suram and Herbig, 2014</xref>; <xref ref-type="bibr" rid="bib109">Van Ly et al., 2018</xref>).</p><p>This Wnt-telomere feedback loop might not be the only regulatory loop at play in AT2 cells. Indeed, we hypothesize that telomeres might be an integrator and amplifier of multiple cellular stress responses. For example, our evidence of upregulation of mitochondrial processes in DC iAT2 cells is consistent with established feedback loops between telomeres and mitochondria: telomere dysfunction can drive mitochondrial dysfunction (<xref ref-type="bibr" rid="bib92">Sahin et al., 2011</xref>) and mitochondrial dysfunction can drive telomere dysfunction (<xref ref-type="bibr" rid="bib31">Guha et al., 2018</xref>; <xref ref-type="bibr" rid="bib80">Passos et al., 2007</xref>; <xref ref-type="bibr" rid="bib85">Qian et al., 2019</xref>). Furthermore, our finding of the upregulation of genes associated with the UPR is consistent with reports linking cellular senescence and the UPR (<xref ref-type="bibr" rid="bib83">Pluquet et al., 2015</xref>). We hypothesize that the UPR might in turn drive telomere dysfunction, and it would thus be of interest to investigate telomere status in familial PF driven by misfolded proteins (<xref ref-type="bibr" rid="bib43">Katzen and Beers, 2020</xref>). These multiple integrated loops might help explain how these various vital cellular processes combine to cause dysfunction in AT2 cells in PF.</p><p>Recent work, using mouse AT2 cell organoids, has elucidated a developmental trajectory by which AT2 cells can differentiate via an intermediate state into type I alveolar epithelial (AT1) cells in response to bleomycin injury (<xref ref-type="bibr" rid="bib17">Choi et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Kobayashi et al., 2020</xref>; <xref ref-type="bibr" rid="bib96">Strunz et al., 2020</xref>). Of note, the intermediate cells are characterized by high levels of p53 signaling and DNA damage which resolve with their final transition to an AT1 cell fate (<xref ref-type="bibr" rid="bib49">Kobayashi et al., 2020</xref>), arguing that repairing DNA damage, potentially at telomeres, is an important step in the transition to an AT1 cell. Furthermore, many of the pathways that promote the differentiation of AT2 cells into AT1 cells are downregulated in DC iAT2 cells, including those involving IL1β, glycolysis, and HIF1α (<xref ref-type="bibr" rid="bib17">Choi et al., 2020</xref>). We speculate that DC AT2 cells with short uncapped telomeres may have trouble suppressing DNA damage at telomeres as they differentiate into AT1 cells. This may lock these cells into the transition state and may help explain their persistence in PF lungs. These persistent transitioning AT2 cells may thereby contribute to fibrosis. Testing this idea in the human iPSC-derived alveolosphere model will require technical advances to enable the generation of AT1 cells. Regardless, our DC iAT2 cell model recapitulates many hallmarks of PF AT2 cells and offers a new system to probe the underlying biology of PF.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><p>See Appendix 1 for Key Resources Table.</p><sec id="s4-1"><title>iPSC line generation and maintenance</title><p>The BU3 NGST line was a generous gift from Dr. Darrell Kotton at Boston University. iPS cells used for differentiation were maintained on growth factor reduced Matrigel (Corning) coated plates in StemMACS iPS-Brew XF medium (Miltenyi Biotec). Cells were cultured in clusters and passaged every 4–5 days using StemMACS Dissociation reagent (Miltenyi Biotec). All iPS lines were genotyped using an RFLP at the relevant important loci, and the sequence was confirmed by Sanger sequencing. All cells were routinely screened for mycoplasma contamination using a PCR-based assay (<xref ref-type="bibr" rid="bib106">Uphoff and Drexler, 2014</xref>).</p></sec><sec id="s4-2"><title>CRISPR editing for generating paired <italic>DKC1</italic> mutant cell lines in BU3 NGST</title><p>To generate the introduced BU3 NGST line harboring the <italic>DKC1</italic> mutation, we used the CRISPR track on the UCSC genome browser to select candidate guideRNAs (gRNAs) that targeted as close to the individual mutation as possible, had easily mutable PAM sites and would introduce a new restriction site to make screening easier (see the Key Resources Table for exact sequences and Figure S1 for details). gRNAs were ordered as oligos from IDT and cloned into pX458, a gift from Dr. Feng Zhang’s lab (Addgene # 48138). The candidate guides were tested for cutting efficiency by transfecting them into HEK293T cells and assaying cutting efficiency using T7E1 digestion of the PCR amplified locus. The most efficient guides were chosen and ssODN HDR templates were designed to eliminate the PAM. iPS cells were then nucleofected with the Amaxa Nucleofection system using the following program (P3, CA-137) (Lonza). The cells were allowed to recover for 36–48 hr at high density in the presence of ROCK inhibitor and then isolated by FACS for GFPhi cells. They were plated at low density (2500 cells/10 cm plate) and allowed to form single colonies. After 7–10 days, individual clones were selected and transferred to 96 well plates and screened for introduction of the restriction site for each mutation. Restriction enzyme positive clones were expanded and then subjected to sanger sequencing for identification of correctly edited clones. Successfully edited clones were checked for normal karyotype by G-banding (Cell Line Genetics), mycoplasma contamination, and pluripotency marker expression by immunofluorescence and were subsequently passaged for at least five passages before being re-genotyped to ensure that the clones were not mixed. During differentiations, all iAT2 cells were genotyped by restriction digest to ensure that the mutation was not lost with passage.</p></sec><sec id="s4-3"><title>Directed differentiation into <italic>NKX2.1+</italic> lung progenitors and <italic>SFTPC+</italic> iPS-derived AT2 cells</title><p>A modified version of the protocol described in <xref ref-type="bibr" rid="bib38">Jacob et al., 2017</xref> was used to generate <italic>SFTPC</italic> expressing iAT2 cells. In brief, iPS cells were seeded at 500,000 cells per well on a six-well plate with ROCK inhibitor for 24 hr and incubated at 5% O2 | 5% CO2 | 90% N2. Definitive endoderm was induced using the StemDiff Definitive Endoderm kit for 3 days. Next, the cells were split at a ratio of 1:3 onto fresh Matrigel plates and anteriorized using dorsomorphin (2 µM) and SB431542 (10 µM) in complete serum-free differentiation media (cSFDM) for 3 days. Cells were then differentiated into <italic>NKX2.1</italic>+ progenitors by incubating in CBRa media (cSFDM containing CHIR99021 [3 µM], BMP4 [10 ng/mL], and retinoic acid [100 nM]) for 7 days changing media every 2 days at first and then increasing to every day media changes when the media became more acidic. On day 15 or 16, <italic>NKX2.1+</italic> progenitors were isolated using a FACSJazz sorter using the endogenous <italic>NKX2.1::GFP</italic> reporter.</p><p><italic>NKX2.1+</italic> sorted cells were re-plated at a density of 400,000 cells/mL in 90% Matrigel supplemented with 10% of CK + DCI + TZV media (cSFDM containing 3 µM CHIR99021, 10 ng/mL KGF, 100 nM dexamethasone, 100 µM 8Br-cAMP and 100 µM IBMX, and 2 µM TZV) (from now on referred to as 90/10 Matrigel). The Matrigel droplets were allowed to cure at 37°C for 20–30 min and then overlaid with an appropriate amount of CK + DCI + TZV media. These alveolosphere containing Matrigel droplets were incubated at 37°C at 20% O2 | 5% CO2 | 75% N2 (room air) for 14 days changing with fresh media every other day. Per Hurely et al., CHIR99021 was withdrawn from the media on day 17 for 4 days and re-added back on day 21 to optimize generation and specification of <italic>SFTPC+</italic> cells. On day 28, the iAT2 containing alveolospheres were sorted on a FACSJazz sorter for SFTPC+ cells using the endogenous <italic>SFTPC::TdTomato</italic> reporter. These sorted SFTPC+ cells were replated at a concentration of 65,000 cells/mL in 90/10 Matrigel drops and grown in K + DCI + TZV at 37°C in an ambient air incubator supplemented to 5% CO2 for 3 weeks changing media every other day.</p></sec><sec id="s4-4"><title>Alveolosphere counting and formation efficiency calculations</title><p>Alveolosphere images were taken on a Leica Thunder widefield microscope using a 1.25× objective. Z-stacks were maximum projected and then thresholded using ImageJ to create a binary file. Binary files were eroded and dilated to ensure maximum determination of the alveolosphere size. Finally, the binary images were separated by watershedding, and alveolospheres were counted using Analyze Particles in ImageJ.</p></sec><sec id="s4-5"><title>Immunofluorescence microscopy of iAT2 alveolospheres</title><p>Alveolospheres were washed with PBS and then fixed in place using 2% paraformaldehyde (PFA) at room temperature for 30 min and then dehydrated and paraffin embedded and sectioned. Once cut, slides were de-paraffinized, rehydrated, permeabilized, and antigens were retrieved by steaming for 15 min in a citrate buffer (Vector Labs). After blocking, each slide was incubated with a primary antibody using the concentrations listed in the Key Resource Table. Slides were incubated with primary antibody at 37°C for 2 hr. After washing, slides were incubated with appropriate fluorochrome conjugated secondary antibodies (see Key Resources Table for antibody details). Slides were then washed, counterstained with DAPI, and mounted. Images were acquired using a Leica Thunder widefield microscope.</p><p>TIFs were stained as described in <xref ref-type="bibr" rid="bib98">Suram et al., 2012</xref>. In brief, cut slides were de-paraffinized, rehydrated, permeabilized, and antigens were retrieved as for other immunofluoresence stains. Slides were blocked and stained for 53BP1 and then stained with an appropriate fluorochrome conjugated secondary antibody. Slides were then re-fixed with PFA, quenched with glycine, re-dehydrated in an ethanol series, and air dried. The slides were then stained with the PNA probe. The slides were washed, rehydrated in an ethanol series, and stained with a tertiary fluorochrome conjugated antibody. Slides were then washed, counterstained with DAPI, and mounted. TIF images were acquired using a Leica SP8 confocal microscope. Quantification of nuclei was carried out in ImageJ in a blinded fashion.</p></sec><sec id="s4-6"><title>Measurement of telomerase activity with TRAP</title><p>iPS cells or iAT2 cells were cultured as indicated in each figure legend. 100,000 cells were harvested using methods described and lysed using NP-40 lysis buffer and processed as described in <xref ref-type="bibr" rid="bib35">Herbert et al., 2006</xref>. In brief, lysates were incubated with a telomerase substrate and incubated at 30°C for telomerase to add telomere repeats. The reactions were then PCR amplified. Telomere repeats were resolved on a 4–20% TBE polyacrylamide gel and visualized by staining with SYBR Green nucleic acid gel stain. Relative telomerase activity was quantified using ImageJ focusing on the first six amplicons averaged across the dilutions.</p></sec><sec id="s4-7"><title>Measurement of telomere lengths by TRF and TeSLA</title><p>Telomere lengths were measured as described in <xref ref-type="bibr" rid="bib55">Lai et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref>. DNA was isolated from cells using a Gentra Puregene kit (Qiagen). DNA was quantified by fluorometry using Qubit 2.0 (Invitrogen). For terminal restriction fragment (TRF) analysis in brief, 500 ng of DNA was digested with CviAII overnight followed by digestion with a mixture of BfaI, MseI, and NdeI overnight. For TeSLA in brief, 50 ng of DNA was ligated to telorette adapters, then digested with CviAII, then digested with a combination of BfaI, MseI, and NdeI, dephosphorylated, and TeSLA adapters (AT/TA Adapters) were ligated on. These TeSLA libraries were PCR amplified using Lucigen’s FailSafe polymerase kit with Pre-Mix H.</p><p>Southern blotting was carried out using previously established protocols with some modification (<xref ref-type="bibr" rid="bib46">Kimura et al., 2010</xref>; <xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref>). TRFs and TeSLA PCR reactions were separated on a 0.7% agarose gel at 0.833 V/cm for 24 hr. The gel was depurinated and denatured and then transferred to a Hybond XL membrane (Cytiva) by capillary transfer using denaturation buffer. The Hybond membrane was hybridized using a DIG-labeled telomere probe overnight. The blot was then washed and exposed using CDP-Star on an LAS-4000 Image Quant imager (Cytiva). TRFs were analyzed using ImageQuant while TeSLAs were analyzed using the MatLab software developed previously (<xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref>).</p></sec><sec id="s4-8"><title>Measurement of telomere lengths by qPCR</title><p>Average telomere length was measured by qPCR as described in <xref ref-type="bibr" rid="bib13">Cawthon, 2002</xref>; <xref ref-type="bibr" rid="bib41">Joglekar et al., 2020</xref> with some modifications. In brief, isolated genomic DNA was quantified by Qubit fluorometry (Invitrogen) and diluted to within the range of a standard curve constructed from a mixture of all samples analyzed. Triplicate qPCR reactions of the telomeric (T) product and the single copy gene (S) (<italic>HBB</italic>) were amplified using a Roche LightCycler 480 II (Roche) using the following programs: T PCR program 95°C for 10 min, 40 cycles of 95°C for 15 s, 56°C for 1 min; S PCR program 95°C for 10 min, 40 cycles of 95°C for 15 s, 58°C for 1 min. Cq values were computed using the second derivative method, and T/S ratios were calculated using the 2<sup>-∆∆Ct</sup> method.</p></sec><sec id="s4-9"><title>RNA-sequencing and data analysis</title><p>SFTPC + sorted cells from the indicated times during, counted and harvested in TRIzol and stored at –80°C until further processing. The RNA was isolated using a Direct-Zol kit (Zymo Research). RNA concentration was obtained by Qubit fluorometry (Invitrogen), and the integrity was checked by tape station analysis (Agilent Technologies). All samples had RINs &gt;8, and the libraries were prepared by poly-A selection and sequenced by GeneWiz, LLC.</p><p>RNA sequencing libraries were prepared using the NEBNext Ultra RNA Library Prep Kit for Illumina following manufacturer’s instructions (NEB). Briefly, mRNAs were first enriched with oligo (dT) beads. Enriched mRNAs were fragmented for 15 min at 94°C. First strand and second strand cDNAs were subsequently synthesized. cDNA fragments were end repaired and adenylated at 3’ ends, and universal adapters were ligated to cDNA fragments, followed by index addition and library enrichment by limited-cycle PCR. The sequencing libraries were validated on the Agilent TapeStation (Agilent Technologies) and quantified using a Qubit 2.0 Fluorometer (Invitrogen) as well as by quantitative PCR (KAPA Biosystems).</p><p>The sequencing libraries were pooled and clustered on one lane of a flowcell. After clustering, the flowcell was loaded on the Illumina HiSeq instrument (4000 or equivalent) according to manufacturer’s instructions. The samples were sequenced using a 2 × 150 bp paired end configuration. Image analysis and base calling were conducted by the HiSeq control software. Raw sequence data (.bcl files) generated from Illumina HiSeq was converted into fastq files and de-multiplexed using Illumina’s bcl2fastq 2.17 software. One mismatch was allowed for index sequence identification.</p><p>Fastq files were checked for quality using FastQC. Raw sequence files (fastq) for 22 samples were mapped using salmon (<ext-link ext-link-type="uri" xlink:href="https://combine-lab.github.io/salmon/">https://combine-lab.github.io/salmon/</ext-link>; <xref ref-type="bibr" rid="bib81">Patro et al., 2017</xref>) against the human transcripts described in Gencode (version v33, built on the human genome GRCm38, <ext-link ext-link-type="uri" xlink:href="https://www.gencodegenes.org">https://www.gencodegenes.org</ext-link>), with a 70.5% average mapping rate yielding 30.4 M average total input reads per sample. Transcript counts were summarized to the gene level using tximport (available <ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/tximport.html">here</ext-link>) and normalized and tested for differential expression using DESeq2 (available <ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html">here</ext-link>). Subsets of time-matched samples were used to compute pair-wise contrast statistics for mutant vs WT at each time. Raw FASTQ files and analyzed counts are available on GEO under the accession number GSE160871.</p><p>GSEA (<xref ref-type="bibr" rid="bib97">Subramanian et al., 2005</xref>) was carried out in R (v4.0.2) (<xref ref-type="bibr" rid="bib86">R Development Core Team, 2020</xref>) using RStudio (v1.3.1056) (<xref ref-type="bibr" rid="bib90">RStudio Team, 2020</xref>), the tidyverse (v1.3.0) (<xref ref-type="bibr" rid="bib112">Wickham et al., 2019</xref>), and the readxl package (v1.3.1) (<xref ref-type="bibr" rid="bib32">Hadley Wickham, 2019</xref>). GSEA was run for contrasts of interest in preranked mode using the DESeq2 statistic as the ranking metric (<xref ref-type="bibr" rid="bib66">Love et al., 2014</xref>). Annotated molecular signatures from the Hallmark Collection (H), Curated Collection (C2), and Regulatory Target Molecular Collection (C3) maintained by the Molecular Signatures Database were accessed in RStudio using the msigdbr package (v7.1.1) (<xref ref-type="bibr" rid="bib22">Dolgalev, 2020</xref>; <xref ref-type="bibr" rid="bib63">Liberzon et al., 2011</xref>; <xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>). The clusterProfiler package (v3.17.1) was used to perform GSEA on the unfiltered, sorted gene lists (<xref ref-type="bibr" rid="bib118">Yu et al., 2012</xref>). GSEA results were viewed using the DT package (v0.15) (<xref ref-type="bibr" rid="bib117">Yihui Xie, 2020</xref>). GSEA plots were generated using the enrichplot package (v1.9.1) (<xref ref-type="bibr" rid="bib120">Yu, 2020</xref>).</p><p>Genes that differed in expression &gt;twofold and were associated with an adjusted p-value &lt;0.05 from the D70 time point were also analyzed through the use of IPA (Ingenuity Systems, <ext-link ext-link-type="uri" xlink:href="https://www.ingenuity.com">https://www.ingenuity.com</ext-link>) (<xref ref-type="bibr" rid="bib52">Krämer et al., 2014</xref>) through the University of Pennsylvania Molecular Profiling Facility.</p></sec><sec id="s4-10"><title>ddPCR</title><p>RNA was isolated as listed above for the RNA-sequencing. 140 ng of RNA was first treated with ezDNAse (Invitrogen) and converted to cDNA using the SuperScript IV First-Strand Synthesis System (Invitrogen). The equivalent of 12.5 ng of original RNA was used as template in the reactions, and the ddPCR assays as well as the ddPCR supermix used are listed in the Key Resources Table (Bio-Rad). ddPCR was performed according to manufacturer’s instructions using QX200 AutoDG Droplet Digital PCR System (Bio-Rad). Results were analyzed using Quanta-Soft Version 1.7.4.0917 (Bio-Rad). Copies/µL were used and normalized to <italic>ACTB</italic>.</p></sec><sec id="s4-11"><title>Statistical methods</title><p>Statistical methods are outlined in each of the figure legends. Each replicate ‘n’ represents an entirely separate differentiation from the pluripotent stem cell stage. For experiments with iPS cells, ‘n’ represents separate wells of the same iPS line (specifically for Figure S1 and S2). Quantitative data is represented as the mean with error bars representing the standard error of the mean. Student’s t-tests (unpaired and two-tailed) were used for determining statistical significance for all comparisons unless otherwise noted.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Visualization</p></fn><fn fn-type="con" id="con3"><p>Methodology</p></fn><fn fn-type="con" id="con4"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Methodology, Resources</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Resources, Software, Visualization</p></fn><fn fn-type="con" id="con14"><p>Data curation, Formal analysis, Resources, Software, Visualization</p></fn><fn fn-type="con" id="con15"><p>Resources</p></fn><fn fn-type="con" id="con16"><p>Resources</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Investigation, Methodology, Project administration, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Gene set enrichment analysis (GSEA) results comparing D70 DC to wild type (WT) iPSC-derived type II alveolar epithelial (iAT2) cells.</title><p>These tables provide the unedited output of the GSEA analysis using the C2 curated gene sets, H hallmark gene sets, and C3 regulatory target gene sets when comparing D70 mutant to WT iAT2 cells. The table reports the name of the gene set (ID), the size of the gene set (setSize), the raw enrichment score (enrichmentScore), the normalized enrichment score, along with the p-value, the adjusted p-value (p.adjust) and false discovery rate q-value (q-values). The ‘core enrichment’ column displays the genes in the gene set.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64430-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Ingenuity pathway analysis (IPA) results comparing D70 dyskeratosis congenita to wild type iPSC-derived type II alveolar epithelial (iAT2) cells.</title><p>These tables provide the unedited output of the IPA. The summary tab lists metadata associated with the analysis. The ‘analysis ready molecules’ lists the differentially expressed genes that differed in expression greater than twofold and were associated with an adjusted p-value &lt; 0.05 from D70 mutant iAT2 cells (DEG list). The ‘canonical pathways tab’ lists pathways curated from the literature and the p-value for enrichment using the DEG list used in the IPA. The ‘upstream regulators’ tab lists the transcription factors, cytokines, and other genetic regulators whose target genes are in the DEG list. ‘Causal networks’ seeks to build a regulatory network based off of the ‘upstream regulators’ to identify master regulators of the DEG list. For more information on interpreting ingenuity analysis results see <xref ref-type="bibr" rid="bib52">Krämer et al., 2014</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64430-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Differentially expressed pathways from D70 dyskeratosis congenita iPSC-derived type II alveolar epithelial (iAT2) cells that are similar to changes seen in pulmonary fibrosis.</title><p>These tables display selected results from gene set enrichment analysis (GSEA) and ingenuity pathway analyses (IPAs) that highlight pathways found to be differentially regulated in mutant iAT2 cells at D70 when compared with wild type cells. The first table displays GSEA results along with the pathway name, normalized enrichment score, and adjusted p-value (D70 p-adj). The second table displays IPA results from the canonical pathways analysis. These are gene sets that are differentially regulated in mutant iAT2 cells at D70 when compared with wild type cells. The p-value reports the significance of enrichment of the molecules in that gene set, and the activation score reports how concordant the gene expression changes are with what is predicted from the literature embedded in IPA (a negative z-score argues that the gene set is down regulated in the mutant iAT2 cells, whereas a positive z-score argues that the gene set is upregulated in mutant iAT2 cells; the lack of a z-score is indicative there was insufficient evidence to provide a z-score.) The ‘molecules’ column lists the genes that were in that gene set that were also found in our differentially expressed gene list when comparing mutant iAT2 cells to wildtype cells.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64430-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-64430-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data was deposited in GEO: GSE160871.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>RJ</given-names></name><name><surname>Johnson</surname><given-names>FB</given-names></name><name><surname>Tobias</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Transcriptional profiling of short telomere iPS-derived sorted SFTPC+ iAT2 cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160871">GSE160871</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank Drs. Eric Witze, Peter Klein, Timothy Olson, Andrew Vaughan, Leo Cardenas, and Aravind Sivakumar for fruitful discussions. We would like to thank Dr. Dong Hun Woo, Carla Hoge, John McCormick, and Dr. Rachel Truitt for help culturing iPS cells, and Dr. Darrell Kotton for providing the BU3 NGST line. We also thank Drs. Erica Carpenter and Jacob Till for help with the ddPCR. This work was also supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Center for Molecular Studies in Digestive and Liver Diseases (P30DK050306) and its Molecular Profiling and Imaging core facilities, by the University of Pennsylvania induced Pluripotent Stem Cell Core and the Penn Genomic Analysis Core, by the Flow Cytometry Core Laboratory, the Human Pluripotent Stem Cell Core at the Children’s Hospital of Philadelphia Research Institute, and the Abramson Cancer Center BioRepository Shared Resource and the Cancer Center Support Grant from the NCI, P30 CA016520.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Loh</surname><given-names>YH</given-names></name><name><surname>McLoughlin</surname><given-names>EM</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>IH</given-names></name><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Huo</surname><given-names>H</given-names></name><name><surname>Okuka</surname><given-names>M</given-names></name><name><surname>Dos Reis</surname><given-names>RM</given-names></name><name><surname>Loewer</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>HH</given-names></name><name><surname>Keefe</surname><given-names>DL</given-names></name><name><surname>Goldman</surname><given-names>FD</given-names></name><name><surname>Klingelhutz</surname><given-names>AJ</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Daley</surname><given-names>GQ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients</article-title><source>Nature</source><volume>464</volume><fpage>292</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nature08792</pub-id><pub-id pub-id-type="pmid">20164838</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita</article-title><source>Hematology/Oncology Clinics of North America</source><volume>32</volume><fpage>669</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2018.04.003</pub-id><pub-id pub-id-type="pmid">30047419</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alder</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>JJL</given-names></name><name><surname>Lancaster</surname><given-names>L</given-names></name><name><surname>Danoff</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Cogan</surname><given-names>JD</given-names></name><name><surname>Vulto</surname><given-names>I</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names></name><name><surname>Lansdorp</surname><given-names>PM</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name><name><surname>Armanios</surname><given-names>MY</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Short telomeres are a risk factor for idiopathic pulmonary fibrosis</article-title><source>PNAS</source><volume>105</volume><fpage>13051</fpage><lpage>13056</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804280105</pub-id><pub-id pub-id-type="pmid">18753630</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alder</surname><given-names>JK</given-names></name><name><surname>Stanley</surname><given-names>SE</given-names></name><name><surname>Wagner</surname><given-names>CL</given-names></name><name><surname>Hamilton</surname><given-names>M</given-names></name><name><surname>Hanumanthu</surname><given-names>VS</given-names></name><name><surname>Armanios</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis</article-title><source>Chest</source><volume>147</volume><fpage>1361</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1378/chest.14-1947</pub-id><pub-id pub-id-type="pmid">25539146</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>An</surname><given-names>WF</given-names></name><name><surname>Germain</surname><given-names>AR</given-names></name><name><surname>Bishop</surname><given-names>JA</given-names></name><name><surname>Nag</surname><given-names>PP</given-names></name><name><surname>Metkar</surname><given-names>S</given-names></name><name><surname>Ketterman</surname><given-names>J</given-names></name><name><surname>Walk</surname><given-names>M</given-names></name><name><surname>Weiwer</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Patnaik</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Discovery of Potent and Highly Selective Inhibitors of GSK3b, Probe Reports from the NIH Molecular Libraries Program</article-title><conf-name>National Center for Biotechnology Information (US</conf-name></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armanios</surname><given-names>MY</given-names></name><name><surname>Chen</surname><given-names>JJL</given-names></name><name><surname>Cogan</surname><given-names>JD</given-names></name><name><surname>Alder</surname><given-names>JK</given-names></name><name><surname>Ingersoll</surname><given-names>RG</given-names></name><name><surname>Markin</surname><given-names>C</given-names></name><name><surname>Lawson</surname><given-names>WE</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Vulto</surname><given-names>I</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names></name><name><surname>Lansdorp</surname><given-names>PM</given-names></name><name><surname>Greider</surname><given-names>CW</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Telomerase mutations in families with idiopathic pulmonary fibrosis</article-title><source>The New England Journal of Medicine</source><volume>356</volume><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa066157</pub-id><pub-id pub-id-type="pmid">17392301</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baarsma</surname><given-names>HA</given-names></name><name><surname>Skronska-Wasek</surname><given-names>W</given-names></name><name><surname>Mutze</surname><given-names>K</given-names></name><name><surname>Ciolek</surname><given-names>F</given-names></name><name><surname>Wagner</surname><given-names>DE</given-names></name><name><surname>John-Schuster</surname><given-names>G</given-names></name><name><surname>Heinzelmann</surname><given-names>K</given-names></name><name><surname>Günther</surname><given-names>A</given-names></name><name><surname>Bracke</surname><given-names>KR</given-names></name><name><surname>Dagouassat</surname><given-names>M</given-names></name><name><surname>Boczkowski</surname><given-names>J</given-names></name><name><surname>Brusselle</surname><given-names>GG</given-names></name><name><surname>Smits</surname><given-names>R</given-names></name><name><surname>Eickelberg</surname><given-names>O</given-names></name><name><surname>Yildirim</surname><given-names>AÖ</given-names></name><name><surname>Königshoff</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Noncanonical WNT-5A signaling impairs endogenous lung repair in COPD</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>143</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1084/jem.20160675</pub-id><pub-id pub-id-type="pmid">27979969</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baena-Del Valle</surname><given-names>JA</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Esopi</surname><given-names>DM</given-names></name><name><surname>Rubenstein</surname><given-names>M</given-names></name><name><surname>Hubbard</surname><given-names>GK</given-names></name><name><surname>Moncaliano</surname><given-names>MC</given-names></name><name><surname>Hruszkewycz</surname><given-names>A</given-names></name><name><surname>Vaghasia</surname><given-names>A</given-names></name><name><surname>Yegnasubramanian</surname><given-names>S</given-names></name><name><surname>Wheelan</surname><given-names>SJ</given-names></name><name><surname>Meeker</surname><given-names>AK</given-names></name><name><surname>Heaphy</surname><given-names>CM</given-names></name><name><surname>Graham</surname><given-names>MK</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer</article-title><source>The Journal of Pathology</source><volume>244</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/path.4980</pub-id><pub-id pub-id-type="pmid">28888037</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkauskas</surname><given-names>CE</given-names></name><name><surname>Cronce</surname><given-names>MJ</given-names></name><name><surname>Rackley</surname><given-names>CR</given-names></name><name><surname>Bowie</surname><given-names>EJ</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Stripp</surname><given-names>BR</given-names></name><name><surname>Randell</surname><given-names>SH</given-names></name><name><surname>Noble</surname><given-names>PW</given-names></name><name><surname>Hogan</surname><given-names>BLM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Type 2 alveolar cells are stem cells in adult lung</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>3025</fpage><lpage>3036</lpage><pub-id pub-id-type="doi">10.1172/JCI68782</pub-id><pub-id pub-id-type="pmid">23921127</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basil</surname><given-names>MC</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lung regeneration: a tale of mice and men</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>100</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2019.11.006</pub-id><pub-id pub-id-type="pmid">31761445</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista</surname><given-names>LFZ</given-names></name><name><surname>Pech</surname><given-names>MF</given-names></name><name><surname>Zhong</surname><given-names>FL</given-names></name><name><surname>Nguyen</surname><given-names>HN</given-names></name><name><surname>Xie</surname><given-names>KT</given-names></name><name><surname>Zaug</surname><given-names>AJ</given-names></name><name><surname>Crary</surname><given-names>SM</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Sebastiano</surname><given-names>V</given-names></name><name><surname>Cherry</surname><given-names>A</given-names></name><name><surname>Giri</surname><given-names>N</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Alter</surname><given-names>BP</given-names></name><name><surname>Cech</surname><given-names>TR</given-names></name><name><surname>Savage</surname><given-names>SA</given-names></name><name><surname>Reijo Pera</surname><given-names>RA</given-names></name><name><surname>Artandi</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells</article-title><source>Nature</source><volume>474</volume><fpage>399</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/nature10084</pub-id><pub-id pub-id-type="pmid">21602826</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullard</surname><given-names>JE</given-names></name><name><surname>Wert</surname><given-names>SE</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Nogee</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>ABCA3 mutations associated with pediatric interstitial lung disease</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>172</volume><fpage>1026</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1164/rccm.200503-504OC</pub-id><pub-id pub-id-type="pmid">15976379</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cawthon</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Telomere measurement by quantitative PCR</article-title><source>Nucleic Acids Research</source><volume>30</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/30.10.e47</pub-id><pub-id pub-id-type="pmid">12000852</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesare</surname><given-names>AJ</given-names></name><name><surname>Kaul</surname><given-names>Z</given-names></name><name><surname>Cohen</surname><given-names>SB</given-names></name><name><surname>Napier</surname><given-names>CE</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name><name><surname>Neumann</surname><given-names>AA</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>16</volume><fpage>1244</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1725</pub-id><pub-id pub-id-type="pmid">19935685</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesare</surname><given-names>AJ</given-names></name><name><surname>Hayashi</surname><given-names>MT</given-names></name><name><surname>Crabbe</surname><given-names>L</given-names></name><name><surname>Karlseder</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The telomere deprotection response is functionally distinct from the genomic DNA damage response</article-title><source>Molecular Cell</source><volume>51</volume><fpage>141</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.06.006</pub-id><pub-id pub-id-type="pmid">23850488</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chilosi</surname><given-names>M</given-names></name><name><surname>Poletti</surname><given-names>V</given-names></name><name><surname>Zamò</surname><given-names>A</given-names></name><name><surname>Lestani</surname><given-names>M</given-names></name><name><surname>Montagna</surname><given-names>L</given-names></name><name><surname>Piccoli</surname><given-names>P</given-names></name><name><surname>Pedron</surname><given-names>S</given-names></name><name><surname>Bertaso</surname><given-names>M</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Murer</surname><given-names>B</given-names></name><name><surname>Cancellieri</surname><given-names>A</given-names></name><name><surname>Maestro</surname><given-names>R</given-names></name><name><surname>Semenzato</surname><given-names>G</given-names></name><name><surname>Doglioni</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis</article-title><source>The American Journal of Pathology</source><volume>162</volume><fpage>1495</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1016/s0002-9440(10)64282-4</pub-id><pub-id pub-id-type="pmid">12707032</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Tsagkogeorga</surname><given-names>G</given-names></name><name><surname>Yanagita</surname><given-names>M</given-names></name><name><surname>Koo</surname><given-names>BK</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inflammatory Signals Induce AT2 Cell-Derived Damage-Associated Transient Progenitors that Mediate Alveolar Regeneration</article-title><source>Cell Stem Cell</source><volume>27</volume><fpage>366</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.06.020</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>K-P</given-names></name><name><surname>Hsu</surname><given-names>C-L</given-names></name><name><surname>Fan</surname><given-names>L-C</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Bhatia</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Hisata</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>SJ</given-names></name><name><surname>Nakahira</surname><given-names>K</given-names></name><name><surname>Imamura</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>ME</given-names></name><name><surname>Yu</surname><given-names>C-J</given-names></name><name><surname>Cloonan</surname><given-names>SM</given-names></name><name><surname>Choi</surname><given-names>AMK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitofusins regulate lipid metabolism to mediate the development of lung fibrosis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3390</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11327-1</pub-id><pub-id pub-id-type="pmid">31358769</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cogan</surname><given-names>JD</given-names></name><name><surname>Kropski</surname><given-names>JA</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Mitchell</surname><given-names>DB</given-names></name><name><surname>Rives</surname><given-names>L</given-names></name><name><surname>Markin</surname><given-names>C</given-names></name><name><surname>Garnett</surname><given-names>ET</given-names></name><name><surname>Montgomery</surname><given-names>KH</given-names></name><name><surname>Mason</surname><given-names>WR</given-names></name><name><surname>McKean</surname><given-names>DF</given-names></name><name><surname>Powers</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Olson</surname><given-names>LM</given-names></name><name><surname>Choi</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>DS</given-names></name><name><surname>Blue</surname><given-names>EM</given-names></name><name><surname>Young</surname><given-names>LR</given-names></name><name><surname>Lancaster</surname><given-names>LH</given-names></name><name><surname>Steele</surname><given-names>MP</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Schwarz</surname><given-names>MI</given-names></name><name><surname>Fingerlin</surname><given-names>TE</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Lawson</surname><given-names>WE</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names></name><name><surname>Blackwell</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rare variants in RTEL1 are associated with familial interstitial pneumonia</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>191</volume><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1164/rccm.201408-1510OC</pub-id><pub-id pub-id-type="pmid">25607374</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietz</surname><given-names>AC</given-names></name><name><surname>Orchard</surname><given-names>PJ</given-names></name><name><surname>Baker</surname><given-names>KS</given-names></name><name><surname>Giller</surname><given-names>RH</given-names></name><name><surname>Savage</surname><given-names>SA</given-names></name><name><surname>Alter</surname><given-names>BP</given-names></name><name><surname>Tolar</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita</article-title><source>Bone Marrow Transplantation</source><volume>46</volume><fpage>98</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/bmt.2010.65</pub-id><pub-id pub-id-type="pmid">20383216</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Disayabutr</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>EK</given-names></name><name><surname>Cha</surname><given-names>S-I</given-names></name><name><surname>Green</surname><given-names>G</given-names></name><name><surname>Naikawadi</surname><given-names>RP</given-names></name><name><surname>Jones</surname><given-names>KD</given-names></name><name><surname>Golden</surname><given-names>JA</given-names></name><name><surname>Schroeder</surname><given-names>A</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Kukreja</surname><given-names>J</given-names></name><name><surname>Erle</surname><given-names>DJ</given-names></name><name><surname>Collard</surname><given-names>HR</given-names></name><name><surname>Wolters</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0158367</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0158367</pub-id><pub-id pub-id-type="pmid">27362652</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Dolgalev</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>msigdbr: MSigDB Gene Sets for Multiple Organisms in a Tidy Data Format</data-title><source>Msigdbr</source></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>IS</given-names></name><name><surname>Diaz del Valle</surname><given-names>F</given-names></name><name><surname>Winn</surname><given-names>RA</given-names></name><name><surname>Voelkel</surname><given-names>NF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Beta-catenin in the fibroproliferative response to acute lung injury</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>34</volume><fpage>274</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2005-0277OC</pub-id><pub-id pub-id-type="pmid">16272459</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driscoll</surname><given-names>B</given-names></name><name><surname>Buckley</surname><given-names>S</given-names></name><name><surname>Bui</surname><given-names>KC</given-names></name><name><surname>Anderson</surname><given-names>KD</given-names></name><name><surname>Warburton</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Telomerase in alveolar epithelial development and repair</article-title><source>American Journal of Physiology. Lung Cellular and Molecular Physiology</source><volume>279</volume><fpage>L1191</fpage><lpage>L1198</lpage><pub-id pub-id-type="doi">10.1152/ajplung.2000.279.6.L1191</pub-id><pub-id pub-id-type="pmid">11076809</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Duckworth</surname><given-names>A</given-names></name><name><surname>Gibbons</surname><given-names>MA</given-names></name><name><surname>Allen</surname><given-names>RJ</given-names></name><name><surname>Almond</surname><given-names>H</given-names></name><name><surname>Beaumont</surname><given-names>RN</given-names></name><name><surname>Wood</surname><given-names>AR</given-names></name><name><surname>Lunnon</surname><given-names>K</given-names></name><name><surname>Lindsay</surname><given-names>MA</given-names></name><name><surname>Wain</surname><given-names>LV</given-names></name><name><surname>Tyrrell</surname><given-names>J</given-names></name><name><surname>Scotton</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evidence That Telomere Length Is Causal for Idiopathic Pulmonary Fibrosis but Not Chronic Obstructive Pulmonary Disease: A Mendelian Randomisation Study</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.02.05.20019653</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everaerts</surname><given-names>S</given-names></name><name><surname>Lammertyn</surname><given-names>EJ</given-names></name><name><surname>Martens</surname><given-names>DS</given-names></name><name><surname>De Sadeleer</surname><given-names>LJ</given-names></name><name><surname>Maes</surname><given-names>K</given-names></name><name><surname>van Batenburg</surname><given-names>AA</given-names></name><name><surname>Goldschmeding</surname><given-names>R</given-names></name><name><surname>van Moorsel</surname><given-names>CHM</given-names></name><name><surname>Dupont</surname><given-names>LJ</given-names></name><name><surname>Wuyts</surname><given-names>WA</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Gayan-Ramirez</surname><given-names>G</given-names></name><name><surname>Kaminski</surname><given-names>N</given-names></name><name><surname>Hogg</surname><given-names>JC</given-names></name><name><surname>Janssens</surname><given-names>W</given-names></name><name><surname>Verleden</surname><given-names>GM</given-names></name><name><surname>Nawrot</surname><given-names>TS</given-names></name><name><surname>Verleden</surname><given-names>SE</given-names></name><name><surname>McDonough</surname><given-names>JE</given-names></name><name><surname>Vanaudenaerde</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The aging lung: tissue telomere shortening in health and disease</article-title><source>Respiratory Research</source><volume>19</volume><elocation-id>95</elocation-id><pub-id pub-id-type="doi">10.1186/s12931-018-0794-z</pub-id><pub-id pub-id-type="pmid">29751799</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>RJ</given-names></name><name><surname>Johnson</surname><given-names>FB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A regulatory loop connecting WNT signaling and telomere capping: possible therapeutic implications for dyskeratosis congenita</article-title><source>Annals of the New York Academy of Sciences</source><volume>1418</volume><fpage>56</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/nyas.13692</pub-id><pub-id pub-id-type="pmid">29722029</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>DB</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Zepp</surname><given-names>JA</given-names></name><name><surname>Snitow</surname><given-names>M</given-names></name><name><surname>Vincent</surname><given-names>TL</given-names></name><name><surname>Penkala</surname><given-names>IJ</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name><name><surname>Herriges</surname><given-names>MJ</given-names></name><name><surname>Morley</surname><given-names>MP</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emergence of a Wave of Wnt Signaling that Regulates Lung Alveologenesis by Controlling Epithelial Self-Renewal and Differentiation</article-title><source>Cell Reports</source><volume>17</volume><fpage>2312</fpage><lpage>2325</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.001</pub-id><pub-id pub-id-type="pmid">27880906</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>NMV</given-names></name><name><surname>Ryder</surname><given-names>OA</given-names></name><name><surname>Houck</surname><given-names>ML</given-names></name><name><surname>Charter</surname><given-names>SJ</given-names></name><name><surname>Walker</surname><given-names>W</given-names></name><name><surname>Forsyth</surname><given-names>NR</given-names></name><name><surname>Austad</surname><given-names>SN</given-names></name><name><surname>Venditti</surname><given-names>C</given-names></name><name><surname>Pagel</surname><given-names>M</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination</article-title><source>Aging Cell</source><volume>10</volume><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1111/j.1474-9726.2011.00718.x</pub-id><pub-id pub-id-type="pmid">21518243</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goss</surname><given-names>AM</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Tsukiyama</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>ED</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Yamaguchi</surname><given-names>TP</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Wnt2/2b and beta-catenin signaling are necessary and sufficient to specify lung progenitors in the foregut</article-title><source>Developmental Cell</source><volume>17</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.005</pub-id><pub-id pub-id-type="pmid">19686689</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guha</surname><given-names>M</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>FB</given-names></name><name><surname>Ruthel</surname><given-names>G</given-names></name><name><surname>Guja</surname><given-names>K</given-names></name><name><surname>Garcia-Diaz</surname><given-names>M</given-names></name><name><surname>Kaufman</surname><given-names>BA</given-names></name><name><surname>Glineburg</surname><given-names>MR</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Basha</surname><given-names>J</given-names></name><name><surname>Kundu</surname><given-names>T</given-names></name><name><surname>Avadhani</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>hnRNPA2 mediated acetylation reduces telomere length in response to mitochondrial dysfunction</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0206897</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0206897</pub-id><pub-id pub-id-type="pmid">30427907</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Hadley Wickham</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>readxl: Read Excel Files</data-title><source>Readxl</source></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haschek</surname><given-names>WM</given-names></name><name><surname>Witschi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Pulmonary fibrosis--a possible mechanism</article-title><source>Toxicology and Applied Pharmacology</source><volume>51</volume><fpage>475</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/0041-008x(79)90372-7</pub-id><pub-id pub-id-type="pmid">538759</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>WR</given-names></name><name><surname>Chi</surname><given-names>EY</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Tien</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Borok</surname><given-names>Z</given-names></name><name><surname>Knight</surname><given-names>DA</given-names></name><name><surname>Kahn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis</article-title><source>PNAS</source><volume>107</volume><fpage>14309</fpage><lpage>14314</lpage><pub-id pub-id-type="doi">10.1073/pnas.1001520107</pub-id><pub-id pub-id-type="pmid">20660310</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbert</surname><given-names>BS</given-names></name><name><surname>Hochreiter</surname><given-names>AE</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol</article-title><source>Nature Protocols</source><volume>1</volume><fpage>1583</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.239</pub-id><pub-id pub-id-type="pmid">17406450</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hesselbarth</surname><given-names>R</given-names></name><name><surname>Esser</surname><given-names>TU</given-names></name><name><surname>Roshanbinfar</surname><given-names>K</given-names></name><name><surname>Schrüfer</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>DW</given-names></name><name><surname>Engel</surname><given-names>FB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CHIR99021 Promotes hiPSC-Derived Cardiomyocyte Proliferation in Engineered 3D Microtissues</article-title><source>Advanced Healthcare Materials</source><volume>10</volume><elocation-id>e2100926</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202100926</pub-id><pub-id pub-id-type="pmid">34499814</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmeyer</surname><given-names>K</given-names></name><name><surname>Raggioli</surname><given-names>A</given-names></name><name><surname>Rudloff</surname><given-names>S</given-names></name><name><surname>Anton</surname><given-names>R</given-names></name><name><surname>Hierholzer</surname><given-names>A</given-names></name><name><surname>Del Valle</surname><given-names>I</given-names></name><name><surname>Hein</surname><given-names>K</given-names></name><name><surname>Vogt</surname><given-names>R</given-names></name><name><surname>Kemler</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells</article-title><source>Science (New York, N.Y.)</source><volume>336</volume><fpage>1549</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1126/science.1218370</pub-id><pub-id pub-id-type="pmid">22723415</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>A</given-names></name><name><surname>Morley</surname><given-names>M</given-names></name><name><surname>Hawkins</surname><given-names>F</given-names></name><name><surname>McCauley</surname><given-names>KB</given-names></name><name><surname>Jean</surname><given-names>JC</given-names></name><name><surname>Heins</surname><given-names>H</given-names></name><name><surname>Na</surname><given-names>CL</given-names></name><name><surname>Weaver</surname><given-names>TE</given-names></name><name><surname>Vedaie</surname><given-names>M</given-names></name><name><surname>Hurley</surname><given-names>K</given-names></name><name><surname>Hinds</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>SJ</given-names></name><name><surname>Kook</surname><given-names>S</given-names></name><name><surname>Zacharias</surname><given-names>W</given-names></name><name><surname>Ochs</surname><given-names>M</given-names></name><name><surname>Traber</surname><given-names>K</given-names></name><name><surname>Quinton</surname><given-names>LJ</given-names></name><name><surname>Crane</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>White</surname><given-names>FV</given-names></name><name><surname>Wambach</surname><given-names>J</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Cole</surname><given-names>FS</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name><name><surname>Guttentag</surname><given-names>SH</given-names></name><name><surname>Beers</surname><given-names>MF</given-names></name><name><surname>Kotton</surname><given-names>DN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells</article-title><source>Cell Stem Cell</source><volume>21</volume><fpage>472</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2017.08.014</pub-id><pub-id pub-id-type="pmid">28965766</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>A.</given-names></name><name><surname>Vedaie</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>DA</given-names></name><name><surname>Thomas</surname><given-names>DC</given-names></name><name><surname>Villacorta-Martin</surname><given-names>C</given-names></name><name><surname>Alysandratos</surname><given-names>KD</given-names></name><name><surname>Hawkins</surname><given-names>F</given-names></name><name><surname>Kotton</surname><given-names>DN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells</article-title><source>Nature Protocols</source><volume>14</volume><fpage>3303</fpage><lpage>3332</lpage><pub-id pub-id-type="doi">10.1038/s41596-019-0220-0</pub-id><pub-id pub-id-type="pmid">31732721</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaitner</surname><given-names>S</given-names></name><name><surname>Reiche</surname><given-names>JA</given-names></name><name><surname>Schäffauer</surname><given-names>AJ</given-names></name><name><surname>Hiendlmeyer</surname><given-names>E</given-names></name><name><surname>Herbst</surname><given-names>H</given-names></name><name><surname>Brabletz</surname><given-names>T</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human telomerase reverse transcriptase (hTERT) is a target gene of β-catenin in human colorectal tumors</article-title><source>Cell Cycle (Georgetown, Tex.)</source><volume>11</volume><fpage>3331</fpage><lpage>3338</lpage><pub-id pub-id-type="doi">10.4161/cc.21790</pub-id><pub-id pub-id-type="pmid">22894902</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joglekar</surname><given-names>MV</given-names></name><name><surname>Satoor</surname><given-names>SN</given-names></name><name><surname>Wong</surname><given-names>WKM</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>RCW</given-names></name><name><surname>Hardikar</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An Optimised Step-by-Step Protocol for Measuring Relative Telomere Length</article-title><source>Methods and Protocols</source><volume>3</volume><elocation-id>E27</elocation-id><pub-id pub-id-type="doi">10.3390/mps3020027</pub-id><pub-id pub-id-type="pmid">32260112</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalina</surname><given-names>M</given-names></name><name><surname>Mason</surname><given-names>RJ</given-names></name><name><surname>Shannon</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Surfactant protein C is expressed in alveolar type II cells but not in Clara cells of rat lung</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>6</volume><fpage>594</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1165/ajrcmb/6.6.594</pub-id><pub-id pub-id-type="pmid">1591008</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzen</surname><given-names>J</given-names></name><name><surname>Beers</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Contributions of alveolar epithelial cell quality control to pulmonary fibrosis</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>5088</fpage><lpage>5099</lpage><pub-id pub-id-type="doi">10.1172/JCI139519</pub-id><pub-id pub-id-type="pmid">32870817</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaul</surname><given-names>Z</given-names></name><name><surname>Cesare</surname><given-names>AJ</given-names></name><name><surname>Huschtscha</surname><given-names>LI</given-names></name><name><surname>Neumann</surname><given-names>AA</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Five dysfunctional telomeres predict onset of senescence in human cells</article-title><source>EMBO Reports</source><volume>13</volume><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/embor.2011.227</pub-id><pub-id pub-id-type="pmid">22157895</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Seo</surname><given-names>JY</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Kwak</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Yoon</surname><given-names>HJ</given-names></name><name><surname>Shin</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Sohn</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Blockade of the Wnt/β-catenin pathway attenuates bleomycin-induced pulmonary fibrosis</article-title><source>The Tohoku Journal of Experimental Medicine</source><volume>223</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1620/tjem.223.45</pub-id><pub-id pub-id-type="pmid">21212602</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>RC</given-names></name><name><surname>Hunt</surname><given-names>SC</given-names></name><name><surname>Skurnick</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Harley</surname><given-names>CB</given-names></name><name><surname>Aviv</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths</article-title><source>Nature Protocols</source><volume>5</volume><fpage>1596</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1038/nprot.2010.124</pub-id><pub-id pub-id-type="pmid">21085125</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>TE</given-names></name><name><surname>Bradford</surname><given-names>WZ</given-names></name><name><surname>Castro-Bernardini</surname><given-names>S</given-names></name><name><surname>Fagan</surname><given-names>EA</given-names></name><name><surname>Glaspole</surname><given-names>I</given-names></name><name><surname>Glassberg</surname><given-names>MK</given-names></name><name><surname>Gorina</surname><given-names>E</given-names></name><name><surname>Hopkins</surname><given-names>PM</given-names></name><name><surname>Kardatzke</surname><given-names>D</given-names></name><name><surname>Lancaster</surname><given-names>L</given-names></name><name><surname>Lederer</surname><given-names>DJ</given-names></name><name><surname>Nathan</surname><given-names>SD</given-names></name><name><surname>Pereira</surname><given-names>CA</given-names></name><name><surname>Sahn</surname><given-names>SA</given-names></name><name><surname>Sussman</surname><given-names>R</given-names></name><name><surname>Swigris</surname><given-names>JJ</given-names></name><name><surname>Noble</surname><given-names>PW</given-names></name><collab>ASCEND Study Group</collab></person-group><year iso-8601-date="2014">2014</year><article-title>A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</article-title><source>The New England Journal of Medicine</source><volume>370</volume><fpage>2083</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1402582</pub-id><pub-id pub-id-type="pmid">24836312</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kneidinger</surname><given-names>N</given-names></name><name><surname>Yildirim</surname><given-names>AÖ</given-names></name><name><surname>Callegari</surname><given-names>J</given-names></name><name><surname>Takenaka</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>MM</given-names></name><name><surname>Dumitrascu</surname><given-names>R</given-names></name><name><surname>Bohla</surname><given-names>A</given-names></name><name><surname>Bracke</surname><given-names>KR</given-names></name><name><surname>Morty</surname><given-names>RE</given-names></name><name><surname>Brusselle</surname><given-names>GG</given-names></name><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Eickelberg</surname><given-names>O</given-names></name><name><surname>Königshoff</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Activation of the WNT/β-catenin pathway attenuates experimental emphysema</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>183</volume><fpage>723</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1164/rccm.200910-1560OC</pub-id><pub-id pub-id-type="pmid">20889911</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Tata</surname><given-names>A</given-names></name><name><surname>Konkimalla</surname><given-names>A</given-names></name><name><surname>Katsura</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>RF</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Banovich</surname><given-names>NE</given-names></name><name><surname>Kropski</surname><given-names>JA</given-names></name><name><surname>Tata</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis</article-title><source>Nature Cell Biology</source><volume>22</volume><fpage>934</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/s41556-020-0542-8</pub-id><pub-id pub-id-type="pmid">32661339</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Königshoff</surname><given-names>M.</given-names></name><name><surname>Balsara</surname><given-names>N</given-names></name><name><surname>Pfaff</surname><given-names>EM</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Chrobak</surname><given-names>I</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Eickelberg</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Functional Wnt signaling is increased in idiopathic pulmonary fibrosis</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e2142</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002142</pub-id><pub-id pub-id-type="pmid">18478089</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Königshoff</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Balsara</surname><given-names>N</given-names></name><name><surname>Wilhelm</surname><given-names>J</given-names></name><name><surname>Amarie</surname><given-names>OV</given-names></name><name><surname>Jahn</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>F</given-names></name><name><surname>Fink</surname><given-names>L</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Schaefer</surname><given-names>L</given-names></name><name><surname>Günther</surname><given-names>A</given-names></name><name><surname>Eickelberg</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis</article-title><source>The Journal of Clinical Investigation</source><volume>119</volume><fpage>772</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1172/JCI33950</pub-id><pub-id pub-id-type="pmid">19287097</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krämer</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Pollard</surname><given-names>J</given-names></name><name><surname>Tugendreich</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Causal analysis approaches in Ingenuity Pathway Analysis</article-title><source>Bioinformatics (Oxford, England)</source><volume>30</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id><pub-id pub-id-type="pmid">24336805</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kropski</surname><given-names>JA</given-names></name><name><surname>Pritchett</surname><given-names>JM</given-names></name><name><surname>Zoz</surname><given-names>DF</given-names></name><name><surname>Crossno</surname><given-names>PF</given-names></name><name><surname>Markin</surname><given-names>C</given-names></name><name><surname>Garnett</surname><given-names>ET</given-names></name><name><surname>Degryse</surname><given-names>AL</given-names></name><name><surname>Mitchell</surname><given-names>DB</given-names></name><name><surname>Polosukhin</surname><given-names>VV</given-names></name><name><surname>Rickman</surname><given-names>OB</given-names></name><name><surname>Choi</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>D-S</given-names></name><name><surname>McConaha</surname><given-names>ME</given-names></name><name><surname>Jones</surname><given-names>BR</given-names></name><name><surname>Gleaves</surname><given-names>LA</given-names></name><name><surname>McMahon</surname><given-names>FB</given-names></name><name><surname>Worrell</surname><given-names>JA</given-names></name><name><surname>Solus</surname><given-names>JF</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Massion</surname><given-names>PP</given-names></name><name><surname>Zaynagetdinov</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>ES</given-names></name><name><surname>Kurtis</surname><given-names>JD</given-names></name><name><surname>Johnson</surname><given-names>JE</given-names></name><name><surname>Groshong</surname><given-names>SD</given-names></name><name><surname>Lancaster</surname><given-names>LH</given-names></name><name><surname>Young</surname><given-names>LR</given-names></name><name><surname>Steele</surname><given-names>MP</given-names></name><name><surname>Phillips Iii</surname><given-names>JA</given-names></name><name><surname>Cogan</surname><given-names>JD</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name><name><surname>Lawson</surname><given-names>WE</given-names></name><name><surname>Blackwell</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>191</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1164/rccm.201406-1162OC</pub-id><pub-id pub-id-type="pmid">25389906</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kropski</surname><given-names>JA</given-names></name><name><surname>Reiss</surname><given-names>S</given-names></name><name><surname>Markin</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Schwarz</surname><given-names>MI</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names></name><name><surname>Blackwell</surname><given-names>TS</given-names></name><name><surname>Cogan</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rare Genetic Variants in PARN Are Associated with Pulmonary Fibrosis in Families</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>196</volume><fpage>1481</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1164/rccm.201703-0635LE</pub-id><pub-id pub-id-type="pmid">28414520</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>TP</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Generation of digoxigenin-incorporated probes to enhance DNA detection sensitivity</article-title><source>BioTechniques</source><volume>60</volume><fpage>306</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.2144/000114427</pub-id><pub-id pub-id-type="pmid">27286808</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>TP</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Noh</surname><given-names>J</given-names></name><name><surname>Mender</surname><given-names>I</given-names></name><name><surname>Tedone</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Danuser</surname><given-names>G</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A method for measuring the distribution of the shortest telomeres in cells and tissues</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1356</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01291-z</pub-id><pub-id pub-id-type="pmid">29116081</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>WE</given-names></name><name><surname>Crossno</surname><given-names>PF</given-names></name><name><surname>Polosukhin</surname><given-names>VV</given-names></name><name><surname>Roldan</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>DS</given-names></name><name><surname>Lane</surname><given-names>KB</given-names></name><name><surname>Blackwell</surname><given-names>TR</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Markin</surname><given-names>C</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Miller</surname><given-names>GG</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name><name><surname>Blackwell</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection</article-title><source>American Journal of Physiology. Lung Cellular and Molecular Physiology</source><volume>294</volume><fpage>L1119</fpage><lpage>L1126</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00382.2007</pub-id><pub-id pub-id-type="pmid">18390830</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lederer</surname><given-names>DJ</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Idiopathic Pulmonary Fibrosis</article-title><source>The New England Journal of Medicine</source><volume>378</volume><fpage>1811</fpage><lpage>1823</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1705751</pub-id><pub-id pub-id-type="pmid">29742380</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name><name><surname>Barsky</surname><given-names>L</given-names></name><name><surname>Scholes</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Driscoll</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Lung alveolar integrity is compromised by telomere shortening in telomerase-null mice</article-title><source>American Journal of Physiology. Lung Cellular and Molecular Physiology</source><volume>296</volume><fpage>L57</fpage><lpage>L70</lpage><pub-id pub-id-type="doi">10.1152/ajplung.90411.2008</pub-id><pub-id pub-id-type="pmid">18952756</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>La</surname><given-names>J</given-names></name><name><surname>Aziz</surname><given-names>S</given-names></name><name><surname>Dobrinskikh</surname><given-names>E</given-names></name><name><surname>Brownell</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>KD</given-names></name><name><surname>Achtar-Zadeh</surname><given-names>N</given-names></name><name><surname>Green</surname><given-names>G</given-names></name><name><surname>Elicker</surname><given-names>BM</given-names></name><name><surname>Golden</surname><given-names>JA</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Kukreja</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Wolters</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Molecular markers of telomere dysfunction and senescence are common findings in the usual interstitial pneumonia pattern of lung fibrosis</article-title><source>Histopathology</source><volume>79</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/his.14334</pub-id><pub-id pub-id-type="pmid">33432658</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Hormi</surname><given-names>K</given-names></name><name><surname>Borok</surname><given-names>Z</given-names></name><name><surname>Minoo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Wnt5a participates in distal lung morphogenesis</article-title><source>Developmental Biology</source><volume>248</volume><fpage>68</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1006/dbio.2002.0729</pub-id><pub-id pub-id-type="pmid">12142021</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>JT</given-names></name><name><surname>Bellusci</surname><given-names>S</given-names></name><name><surname>Delanghe</surname><given-names>S</given-names></name><name><surname>Minoo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Wnt5a regulates Shh and Fgf10 signaling during lung development</article-title><source>Developmental Biology</source><volume>287</volume><fpage>86</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2005.08.035</pub-id><pub-id pub-id-type="pmid">16169547</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Pinchback</surname><given-names>R</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular signatures database (MSigDB) 3.0</article-title><source>Bioinformatics (Oxford, England)</source><volume>27</volume><fpage>1739</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr260</pub-id><pub-id pub-id-type="pmid">21546393</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Koh</surname><given-names>PW</given-names></name><name><surname>Deng</surname><given-names>TZ</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Tsai</surname><given-names>JM</given-names></name><name><surname>Barkal</surname><given-names>AA</given-names></name><name><surname>Shen</surname><given-names>KY</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Morganti</surname><given-names>RM</given-names></name><name><surname>Shyh-Chang</surname><given-names>N</given-names></name><name><surname>Fernhoff</surname><given-names>NB</given-names></name><name><surname>George</surname><given-names>BM</given-names></name><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Salomon</surname><given-names>REA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Talbot</surname><given-names>WS</given-names></name><name><surname>Beachy</surname><given-names>PA</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mapping the Pairwise Choices Leading from Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types</article-title><source>Cell</source><volume>166</volume><fpage>451</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.011</pub-id><pub-id pub-id-type="pmid">27419872</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Hua</surname><given-names>F</given-names></name><name><surname>Cui</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The cell cycle inhibitor P21 promotes the development of pulmonary fibrosis by suppressing lung alveolar regeneration</article-title><source>Acta Pharmaceutica Sinica B</source><volume>12</volume><fpage>735</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.07.015</pub-id><pub-id pub-id-type="pmid">35256943</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitra</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gerard</surname><given-names>RD</given-names></name><name><surname>Mendelson</surname><given-names>CR</given-names></name><name><surname>Garcia</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Surfactant Protein A2 Mutations Associated with Pulmonary Fibrosis Lead to Protein Instability and Endoplasmic Reticulum Stress</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>22103</fpage><lpage>22113</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.121467</pub-id><pub-id pub-id-type="pmid">20466729</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maretto</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Braghetta</surname><given-names>P</given-names></name><name><surname>Broccoli</surname><given-names>V</given-names></name><name><surname>Hassan</surname><given-names>AB</given-names></name><name><surname>Volpin</surname><given-names>D</given-names></name><name><surname>Bressan</surname><given-names>GM</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mapping Wnt/β-catenin signaling during mouse development and in colorectal tumors</article-title><source>PNAS</source><volume>100</volume><fpage>3299</fpage><lpage>3304</lpage><pub-id pub-id-type="doi">10.1073/pnas.0434590100</pub-id><pub-id pub-id-type="pmid">12626757</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Ruiz</surname><given-names>C</given-names></name><name><surname>Saretzki</surname><given-names>G</given-names></name><name><surname>Petrie</surname><given-names>J</given-names></name><name><surname>Ladhoff</surname><given-names>J</given-names></name><name><surname>Jeyapalan</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Sedivy</surname><given-names>J</given-names></name><name><surname>von Zglinicki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Stochastic variation in telomere shortening rate causes heterogeneity of human fibroblast replicative life span</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>17826</fpage><lpage>17833</lpage><pub-id pub-id-type="doi">10.1074/jbc.M311980200</pub-id><pub-id pub-id-type="pmid">14963037</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonough</surname><given-names>JE</given-names></name><name><surname>Ahangari</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Verleden</surname><given-names>SE</given-names></name><name><surname>Herazo-Maya</surname><given-names>J</given-names></name><name><surname>Vukmirovic</surname><given-names>M</given-names></name><name><surname>DeIuliis</surname><given-names>G</given-names></name><name><surname>Tzouvelekis</surname><given-names>A</given-names></name><name><surname>Tanabe</surname><given-names>N</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Verschakelen</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Manatakis</surname><given-names>DV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Maes</surname><given-names>K</given-names></name><name><surname>De Sadeleer</surname><given-names>L</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Neyrinck</surname><given-names>A</given-names></name><name><surname>Benos</surname><given-names>PV</given-names></name><name><surname>Bar-Joseph</surname><given-names>Z</given-names></name><name><surname>Tantin</surname><given-names>D</given-names></name><name><surname>Hogg</surname><given-names>JC</given-names></name><name><surname>Vanaudenaerde</surname><given-names>BM</given-names></name><name><surname>Wuyts</surname><given-names>WA</given-names></name><name><surname>Kaminski</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptional regulatory model of fibrosis progression in the human lung</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>131597</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.131597</pub-id><pub-id pub-id-type="pmid">31600171</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikels</surname><given-names>AJ</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context</article-title><source>PLOS Biology</source><volume>4</volume><elocation-id>040115</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0040115</pub-id><pub-id pub-id-type="pmid">16602827</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulugeta</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Russo</surname><given-names>SJ</given-names></name><name><surname>Muniswamy</surname><given-names>M</given-names></name><name><surname>Beers</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>32</volume><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2005-0009OC</pub-id><pub-id pub-id-type="pmid">15778495</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabhan</surname><given-names>AN</given-names></name><name><surname>Brownfield</surname><given-names>DG</given-names></name><name><surname>Harbury</surname><given-names>PB</given-names></name><name><surname>Krasnow</surname><given-names>MA</given-names></name><name><surname>Desai</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells</article-title><source>Science (New York, N.Y.)</source><volume>359</volume><fpage>1118</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1126/science.aam6603</pub-id><pub-id pub-id-type="pmid">29420258</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naikawadi</surname><given-names>RP</given-names></name><name><surname>Disayabutr</surname><given-names>S</given-names></name><name><surname>Mallavia</surname><given-names>B</given-names></name><name><surname>Donne</surname><given-names>ML</given-names></name><name><surname>Green</surname><given-names>G</given-names></name><name><surname>La</surname><given-names>JL</given-names></name><name><surname>Rock</surname><given-names>JR</given-names></name><name><surname>Looney</surname><given-names>MR</given-names></name><name><surname>Wolters</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis</article-title><source>JCI Insight</source><volume>1</volume><elocation-id>e86704</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.86704</pub-id><pub-id pub-id-type="pmid">27699234</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nureki</surname><given-names>S-I</given-names></name><name><surname>Tomer</surname><given-names>Y</given-names></name><name><surname>Venosa</surname><given-names>A</given-names></name><name><surname>Katzen</surname><given-names>J</given-names></name><name><surname>Russo</surname><given-names>SJ</given-names></name><name><surname>Jamil</surname><given-names>S</given-names></name><name><surname>Barrett</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Kopp</surname><given-names>M</given-names></name><name><surname>Mulugeta</surname><given-names>S</given-names></name><name><surname>Beers</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis</article-title><source>The Journal of Clinical Investigation</source><volume>128</volume><fpage>4008</fpage><lpage>4024</lpage><pub-id pub-id-type="doi">10.1172/JCI99287</pub-id><pub-id pub-id-type="pmid">29920187</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okubo</surname><given-names>T</given-names></name><name><surname>Hogan</surname><given-names>BLM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hyperactive Wnt signaling changes the developmental potential of embryonic lung endoderm</article-title><source>Journal of Biology</source><volume>3</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1186/jbiol3</pub-id><pub-id pub-id-type="pmid">15186480</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrin</surname><given-names>EJ</given-names></name><name><surname>Little</surname><given-names>DR</given-names></name><name><surname>Gerner-Mauro</surname><given-names>KN</given-names></name><name><surname>Sumner</surname><given-names>EA</given-names></name><name><surname>Ríos-Corzo</surname><given-names>R</given-names></name><name><surname>Ambrosio</surname><given-names>E</given-names></name><name><surname>Holt</surname><given-names>SE</given-names></name><name><surname>Forcioli-Conti</surname><given-names>N</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Hanash</surname><given-names>SM</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>SXL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>β-Catenin maintains lung epithelial progenitors after lung specification</article-title><source>Development (Cambridge, England)</source><volume>145</volume><elocation-id>dev160788</elocation-id><pub-id pub-id-type="doi">10.1242/dev.160788</pub-id><pub-id pub-id-type="pmid">29440304</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliuca</surname><given-names>FW</given-names></name><name><surname>Millman</surname><given-names>JR</given-names></name><name><surname>Gürtler</surname><given-names>M</given-names></name><name><surname>Segel</surname><given-names>M</given-names></name><name><surname>Van Dervort</surname><given-names>A</given-names></name><name><surname>Ryu</surname><given-names>JH</given-names></name><name><surname>Peterson</surname><given-names>QP</given-names></name><name><surname>Greiner</surname><given-names>D</given-names></name><name><surname>Melton</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Generation of functional human pancreatic β cells in vitro</article-title><source>Cell</source><volume>159</volume><fpage>428</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.040</pub-id><pub-id pub-id-type="pmid">25303535</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passos</surname><given-names>JF</given-names></name><name><surname>Saretzki</surname><given-names>G</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>G</given-names></name><name><surname>Richter</surname><given-names>T</given-names></name><name><surname>Peters</surname><given-names>H</given-names></name><name><surname>Wappler</surname><given-names>I</given-names></name><name><surname>Birket</surname><given-names>MJ</given-names></name><name><surname>Harold</surname><given-names>G</given-names></name><name><surname>Schaeuble</surname><given-names>K</given-names></name><name><surname>Birch-Machin</surname><given-names>MA</given-names></name><name><surname>Kirkwood</surname><given-names>TBL</given-names></name><name><surname>von Zglinicki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence</article-title><source>PLOS Biology</source><volume>5</volume><elocation-id>e050110</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0050110</pub-id><pub-id pub-id-type="pmid">17472436</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname><given-names>R</given-names></name><name><surname>Duggal</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Kingsford</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perera</surname><given-names>ON</given-names></name><name><surname>Sobinoff</surname><given-names>AP</given-names></name><name><surname>Teber</surname><given-names>ET</given-names></name><name><surname>Harman</surname><given-names>A</given-names></name><name><surname>Maritz</surname><given-names>MF</given-names></name><name><surname>Yang</surname><given-names>SF</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name><name><surname>Cesare</surname><given-names>AJ</given-names></name><name><surname>Arthur</surname><given-names>JW</given-names></name><name><surname>MacKenzie</surname><given-names>KL</given-names></name><name><surname>Bryan</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Telomerase promotes formation of a telomere protective complex in cancer cells</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaav4409</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aav4409</pub-id><pub-id pub-id-type="pmid">31616780</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pluquet</surname><given-names>O</given-names></name><name><surname>Pourtier</surname><given-names>A</given-names></name><name><surname>Abbadie</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The unfolded protein response and cellular senescence. A review in the theme: cellular mechanisms of endoplasmic reticulum stress signaling in health and disease</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>308</volume><fpage>C415</fpage><lpage>C425</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00334.2014</pub-id><pub-id pub-id-type="pmid">25540175</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Povedano</surname><given-names>JM</given-names></name><name><surname>Martinez</surname><given-names>P</given-names></name><name><surname>Flores</surname><given-names>JM</given-names></name><name><surname>Mulero</surname><given-names>F</given-names></name><name><surname>Blasco</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mice with Pulmonary Fibrosis Driven by Telomere Dysfunction</article-title><source>Cell Reports</source><volume>12</volume><fpage>286</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.06.028</pub-id><pub-id pub-id-type="pmid">26146081</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Roginskaya</surname><given-names>V</given-names></name><name><surname>Fouquerel</surname><given-names>E</given-names></name><name><surname>Opresko</surname><given-names>PL</given-names></name><name><surname>Shiva</surname><given-names>S</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>Kolodieznyi</surname><given-names>D</given-names></name><name><surname>Bruchez</surname><given-names>MP</given-names></name><name><surname>Van Houten</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chemoptogenetic damage to mitochondria causes rapid telomere dysfunction</article-title><source>PNAS</source><volume>116</volume><fpage>18435</fpage><lpage>18444</lpage><pub-id pub-id-type="doi">10.1073/pnas.1910574116</pub-id><pub-id pub-id-type="pmid">31451640</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2020">2020</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezania</surname><given-names>A</given-names></name><name><surname>Bruin</surname><given-names>JE</given-names></name><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Rubin</surname><given-names>A</given-names></name><name><surname>Batushansky</surname><given-names>I</given-names></name><name><surname>Asadi</surname><given-names>A</given-names></name><name><surname>O’Dwyer</surname><given-names>S</given-names></name><name><surname>Quiskamp</surname><given-names>N</given-names></name><name><surname>Mojibian</surname><given-names>M</given-names></name><name><surname>Albrecht</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>YHC</given-names></name><name><surname>Johnson</surname><given-names>JD</given-names></name><name><surname>Kieffer</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>1121</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/nbt.3033</pub-id><pub-id pub-id-type="pmid">25211370</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richeldi</surname><given-names>L</given-names></name><name><surname>du Bois</surname><given-names>RM</given-names></name><name><surname>Raghu</surname><given-names>G</given-names></name><name><surname>Azuma</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Costabel</surname><given-names>U</given-names></name><name><surname>Cottin</surname><given-names>V</given-names></name><name><surname>Flaherty</surname><given-names>KR</given-names></name><name><surname>Hansell</surname><given-names>DM</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Kolb</surname><given-names>M</given-names></name><name><surname>Nicholson</surname><given-names>AG</given-names></name><name><surname>Noble</surname><given-names>PW</given-names></name><name><surname>Selman</surname><given-names>M</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Brun</surname><given-names>M</given-names></name><name><surname>Le Maulf</surname><given-names>F</given-names></name><name><surname>Girard</surname><given-names>M</given-names></name><name><surname>Stowasser</surname><given-names>S</given-names></name><name><surname>Schlenker-Herceg</surname><given-names>R</given-names></name><name><surname>Disse</surname><given-names>B</given-names></name><name><surname>Collard</surname><given-names>HR</given-names></name><collab>INPULSIS Trial Investigators</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</article-title><source>The New England Journal of Medicine</source><volume>370</volume><fpage>2071</fpage><lpage>2082</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1402584</pub-id><pub-id pub-id-type="pmid">24836310</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>DB</given-names></name><name><surname>Johnson</surname><given-names>KW</given-names></name><name><surname>Henriksen</surname><given-names>EJ</given-names></name><name><surname>Nuss</surname><given-names>JM</given-names></name><name><surname>Goff</surname><given-names>D</given-names></name><name><surname>Kinnick</surname><given-names>TR</given-names></name><name><surname>Ma</surname><given-names>ST</given-names></name><name><surname>Reeder</surname><given-names>JW</given-names></name><name><surname>Samuels</surname><given-names>I</given-names></name><name><surname>Slabiak</surname><given-names>T</given-names></name><name><surname>Wagman</surname><given-names>AS</given-names></name><name><surname>Hammond</surname><given-names>M-EW</given-names></name><name><surname>Harrison</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo</article-title><source>Diabetes</source><volume>52</volume><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.3.588</pub-id><pub-id pub-id-type="pmid">12606497</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="software"><person-group person-group-type="author"><collab>RStudio Team</collab></person-group><year iso-8601-date="2020">2020</year><data-title>RStudio: Integrated Development Environment for R</data-title><source>RStudio, PBC</source></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruis</surname><given-names>P</given-names></name><name><surname>Boulton</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The end protection problem-an unexpected twist in the tail</article-title><source>Genes &amp; Development</source><volume>35</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1101/gad.344044.120</pub-id><pub-id pub-id-type="pmid">33361389</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>E</given-names></name><name><surname>Colla</surname><given-names>S</given-names></name><name><surname>Liesa</surname><given-names>M</given-names></name><name><surname>Moslehi</surname><given-names>J</given-names></name><name><surname>Müller</surname><given-names>FL</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Kotton</surname><given-names>D</given-names></name><name><surname>Fabian</surname><given-names>AJ</given-names></name><name><surname>Walkey</surname><given-names>C</given-names></name><name><surname>Maser</surname><given-names>RS</given-names></name><name><surname>Tonon</surname><given-names>G</given-names></name><name><surname>Foerster</surname><given-names>F</given-names></name><name><surname>Xiong</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>YA</given-names></name><name><surname>Shukla</surname><given-names>SA</given-names></name><name><surname>Jaskelioff</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>ES</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Protopopov</surname><given-names>A</given-names></name><name><surname>Ivanova</surname><given-names>E</given-names></name><name><surname>Mahoney</surname><given-names>JE</given-names></name><name><surname>Kost-Alimova</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>SR</given-names></name><name><surname>Bronson</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>R</given-names></name><name><surname>Mulligan</surname><given-names>R</given-names></name><name><surname>Shirihai</surname><given-names>OS</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Telomere dysfunction induces metabolic and mitochondrial compromise</article-title><source>Nature</source><volume>470</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1038/nature09787</pub-id><pub-id pub-id-type="pmid">21307849</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>SK</given-names></name><name><surname>Tiwari</surname><given-names>N</given-names></name><name><surname>Marudamuthu</surname><given-names>AS</given-names></name><name><surname>Puthusseri</surname><given-names>B</given-names></name><name><surname>Bhandary</surname><given-names>YP</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Levin</surname><given-names>J</given-names></name><name><surname>Idell</surname><given-names>S</given-names></name><name><surname>Shetty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis</article-title><source>The American Journal of Pathology</source><volume>187</volume><fpage>1016</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2016.12.020</pub-id><pub-id pub-id-type="pmid">28273432</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>W</given-names></name><name><surname>Guttentag</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Ballard</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Millar</surname><given-names>SE</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung</article-title><source>Developmental Biology</source><volume>283</volume><fpage>226</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2005.04.014</pub-id><pub-id pub-id-type="pmid">15907834</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snetselaar</surname><given-names>R</given-names></name><name><surname>van Batenburg</surname><given-names>AA</given-names></name><name><surname>van Oosterhout</surname><given-names>MFM</given-names></name><name><surname>Kazemier</surname><given-names>KM</given-names></name><name><surname>Roothaan</surname><given-names>SM</given-names></name><name><surname>Peeters</surname><given-names>T</given-names></name><name><surname>van der Vis</surname><given-names>JJ</given-names></name><name><surname>Goldschmeding</surname><given-names>R</given-names></name><name><surname>Grutters</surname><given-names>JC</given-names></name><name><surname>van Moorsel</surname><given-names>CHM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Short telomere length in IPF lung associates with fibrotic lesions and predicts survival</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0189467</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0189467</pub-id><pub-id pub-id-type="pmid">29281671</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strunz</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>LM</given-names></name><name><surname>Ansari</surname><given-names>M</given-names></name><name><surname>Kathiriya</surname><given-names>JJ</given-names></name><name><surname>Angelidis</surname><given-names>I</given-names></name><name><surname>Mayr</surname><given-names>CH</given-names></name><name><surname>Tsidiridis</surname><given-names>G</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Mattner</surname><given-names>LF</given-names></name><name><surname>Yee</surname><given-names>M</given-names></name><name><surname>Ogar</surname><given-names>P</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Kukhtevich</surname><given-names>I</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Voss</surname><given-names>C</given-names></name><name><surname>Stoeger</surname><given-names>T</given-names></name><name><surname>Neumann</surname><given-names>JHL</given-names></name><name><surname>Hilgendorff</surname><given-names>A</given-names></name><name><surname>Behr</surname><given-names>J</given-names></name><name><surname>O’Reilly</surname><given-names>M</given-names></name><name><surname>Lehmann</surname><given-names>M</given-names></name><name><surname>Burgstaller</surname><given-names>G</given-names></name><name><surname>Königshoff</surname><given-names>M</given-names></name><name><surname>Chapman</surname><given-names>HA</given-names></name><name><surname>Theis</surname><given-names>FJ</given-names></name><name><surname>Schiller</surname><given-names>HB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3559</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17358-3</pub-id><pub-id pub-id-type="pmid">32678092</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suram</surname><given-names>A</given-names></name><name><surname>Kaplunov</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>PL</given-names></name><name><surname>Ruan</surname><given-names>H</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name><name><surname>Boccardi</surname><given-names>V</given-names></name><name><surname>Fumagalli</surname><given-names>M</given-names></name><name><surname>Di Micco</surname><given-names>R</given-names></name><name><surname>Mirani</surname><given-names>N</given-names></name><name><surname>Gurung</surname><given-names>RL</given-names></name><name><surname>Hande</surname><given-names>MP</given-names></name><name><surname>d’Adda di Fagagna</surname><given-names>F</given-names></name><name><surname>Herbig</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>2839</fpage><lpage>2851</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.132</pub-id><pub-id pub-id-type="pmid">22569128</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suram</surname><given-names>A.</given-names></name><name><surname>Herbig</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The replicometer is broken: telomeres activate cellular senescence in response to genotoxic stresses</article-title><source>Aging Cell</source><volume>13</volume><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1111/acel.12246</pub-id><pub-id pub-id-type="pmid">25040628</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>H</given-names></name><name><surname>Smogorzewska</surname><given-names>A</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>DNA damage foci at dysfunctional telomeres</article-title><source>Current Biology</source><volume>13</volume><fpage>1549</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(03)00542-6</pub-id><pub-id pub-id-type="pmid">12956959</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanjore</surname><given-names>H</given-names></name><name><surname>Degryse</surname><given-names>AL</given-names></name><name><surname>Crossno</surname><given-names>PF</given-names></name><name><surname>Xu</surname><given-names>XC</given-names></name><name><surname>McConaha</surname><given-names>ME</given-names></name><name><surname>Jones</surname><given-names>BR</given-names></name><name><surname>Polosukhin</surname><given-names>VV</given-names></name><name><surname>Bryant</surname><given-names>AJ</given-names></name><name><surname>Cheng</surname><given-names>D-S</given-names></name><name><surname>Newcomb</surname><given-names>DC</given-names></name><name><surname>McMahon</surname><given-names>FB</given-names></name><name><surname>Gleaves</surname><given-names>LA</given-names></name><name><surname>Blackwell</surname><given-names>TS</given-names></name><name><surname>Lawson</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>β-catenin in the alveolar epithelium protects from lung fibrosis after intratracheal bleomycin</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>187</volume><fpage>630</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1164/rccm.201205-0972OC</pub-id><pub-id pub-id-type="pmid">23306543</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Telomeres Mendelian Randomization Collaboration</collab><name><surname>Haycock</surname><given-names>PC</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Nounu</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Okoli</surname><given-names>GN</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Wade</surname><given-names>KH</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Willeit</surname><given-names>P</given-names></name><name><surname>Aviv</surname><given-names>A</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>HP</given-names></name><name><surname>Kurian</surname><given-names>KM</given-names></name><name><surname>Pooley</surname><given-names>KA</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Law</surname><given-names>MH</given-names></name><name><surname>Bowdler</surname><given-names>LM</given-names></name><name><surname>Iles</surname><given-names>MM</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Worrall</surname><given-names>BB</given-names></name><name><surname>Markus</surname><given-names>HS</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Thompson</surname><given-names>DJ</given-names></name><name><surname>O’Mara</surname><given-names>TA</given-names></name><name><surname>Wolpin</surname><given-names>B</given-names></name><name><surname>Amundadottir</surname><given-names>L</given-names></name><name><surname>Stolzenberg-Solomon</surname><given-names>R</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Onland-Moret</surname><given-names>NC</given-names></name><name><surname>Lund</surname><given-names>E</given-names></name><name><surname>Duell</surname><given-names>EJ</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Gunter</surname><given-names>MJ</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Svenson</surname><given-names>U</given-names></name><name><surname>van Rij</surname><given-names>A</given-names></name><name><surname>Baas</surname><given-names>AF</given-names></name><name><surname>Bown</surname><given-names>MJ</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>van t’Hof</surname><given-names>FNG</given-names></name><name><surname>Tromp</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>GT</given-names></name><name><surname>Kuivaniemi</surname><given-names>H</given-names></name><name><surname>Elmore</surname><given-names>JR</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Mckay</surname><given-names>J</given-names></name><name><surname>Scelo</surname><given-names>G</given-names></name><name><surname>Carreras-Torres</surname><given-names>R</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Bracci</surname><given-names>PM</given-names></name><name><surname>Neale</surname><given-names>RE</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>Risch</surname><given-names>HA</given-names></name><name><surname>Klein</surname><given-names>AP</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Abnet</surname><given-names>CC</given-names></name><name><surname>Freedman</surname><given-names>ND</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Maris</surname><given-names>JM</given-names></name><name><surname>Aben</surname><given-names>KK</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Vermeulen</surname><given-names>SH</given-names></name><name><surname>Wiencke</surname><given-names>JK</given-names></name><name><surname>Walsh</surname><given-names>KM</given-names></name><name><surname>Wrensch</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>T</given-names></name><name><surname>Turnbull</surname><given-names>C</given-names></name><name><surname>Litchfield</surname><given-names>K</given-names></name><name><surname>Paternoster</surname><given-names>L</given-names></name><name><surname>Standl</surname><given-names>M</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>SanGiovanni</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Mijatovic</surname><given-names>V</given-names></name><name><surname>Sapkota</surname><given-names>Y</given-names></name><name><surname>Low</surname><given-names>S-K</given-names></name><name><surname>Zondervan</surname><given-names>KT</given-names></name><name><surname>Montgomery</surname><given-names>GW</given-names></name><name><surname>Nyholt</surname><given-names>DR</given-names></name><name><surname>van Heel</surname><given-names>DA</given-names></name><name><surname>Hunt</surname><given-names>K</given-names></name><name><surname>Arking</surname><given-names>DE</given-names></name><name><surname>Ashar</surname><given-names>FN</given-names></name><name><surname>Sotoodehnia</surname><given-names>N</given-names></name><name><surname>Woo</surname><given-names>D</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Comeau</surname><given-names>ME</given-names></name><name><surname>Brown</surname><given-names>WM</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Cho</surname><given-names>MH</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><name><surname>Thompson</surname><given-names>PJ</given-names></name><name><surname>Morrison</surname><given-names>AC</given-names></name><name><surname>Felix</surname><given-names>JF</given-names></name><name><surname>Smith</surname><given-names>NL</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>Petukhova</surname><given-names>L</given-names></name><name><surname>Betz</surname><given-names>RC</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Langefeld</surname><given-names>CD</given-names></name><name><surname>Thompson</surname><given-names>SD</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Fingerlin</surname><given-names>T</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Cotch</surname><given-names>MF</given-names></name><name><surname>Jensen</surname><given-names>RA</given-names></name><name><surname>Munz</surname><given-names>M</given-names></name><name><surname>Dommisch</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>AS</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Ollila</surname><given-names>HM</given-names></name><name><surname>Hillary</surname><given-names>RP</given-names></name><name><surname>Albagha</surname><given-names>O</given-names></name><name><surname>Ralston</surname><given-names>SH</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>X-O</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name><name><surname>Uebe</surname><given-names>S</given-names></name><name><surname>Hüffmeier</surname><given-names>U</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Otowa</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Davila</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>G</given-names></name><name><surname>Siminovitch</surname><given-names>K</given-names></name><name><surname>Bei</surname><given-names>J-X</given-names></name><name><surname>Zeng</surname><given-names>Y-X</given-names></name><name><surname>Försti</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Landi</surname><given-names>S</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Ellinghaus</surname><given-names>D</given-names></name><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Noth</surname><given-names>I</given-names></name><name><surname>Ma</surname><given-names>S-F</given-names></name><name><surname>Foo</surname><given-names>JN</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J-W</given-names></name><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Mirabeau</surname><given-names>O</given-names></name><name><surname>Skibola</surname><given-names>CF</given-names></name><name><surname>Tang</surname><given-names>CS</given-names></name><name><surname>Garcia-Barcelo</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>K-P</given-names></name><name><surname>Su</surname><given-names>W-H</given-names></name><name><surname>Chang</surname><given-names>Y-S</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Wade</surname><given-names>TD</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Cha</surname><given-names>P-C</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Hwang</surname><given-names>S-J</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Spector</surname><given-names>T</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Manichaikul</surname><given-names>AW</given-names></name><name><surname>Barr</surname><given-names>RG</given-names></name><name><surname>Kahali</surname><given-names>B</given-names></name><name><surname>Speliotes</surname><given-names>E</given-names></name><name><surname>Yerges-Armstrong</surname><given-names>LM</given-names></name><name><surname>Cheng</surname><given-names>C-Y</given-names></name><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Fogh</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Powell</surname><given-names>JF</given-names></name><name><surname>Rice</surname><given-names>K</given-names></name><name><surname>Relton</surname><given-names>CL</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study</article-title><source>JAMA Oncology</source><volume>3</volume><fpage>636</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.5945</pub-id><pub-id pub-id-type="pmid">28241208</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>AKK</given-names></name><name><surname>Valdez</surname><given-names>IA</given-names></name><name><surname>Dirice</surname><given-names>E</given-names></name><name><surname>Kulkarni</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comparable generation of activin-induced definitive endoderm via additive Wnt or BMP signaling in absence of serum</article-title><source>Stem Cell Reports</source><volume>3</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2014.05.007</pub-id><pub-id pub-id-type="pmid">25068117</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>AQ</given-names></name><name><surname>Lane</surname><given-names>K</given-names></name><name><surname>Phillips</surname><given-names>J</given-names></name><name><surname>Prince</surname><given-names>M</given-names></name><name><surname>Markin</surname><given-names>C</given-names></name><name><surname>Speer</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Gaddipati</surname><given-names>R</given-names></name><name><surname>Marney</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Haines</surname><given-names>J</given-names></name><name><surname>Stahlman</surname><given-names>M</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>165</volume><fpage>1322</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1164/rccm.200112-123OC</pub-id><pub-id pub-id-type="pmid">11991887</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhl</surname><given-names>FE</given-names></name><name><surname>Vierkotten</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>DE</given-names></name><name><surname>Burgstaller</surname><given-names>G</given-names></name><name><surname>Costa</surname><given-names>R</given-names></name><name><surname>Koch</surname><given-names>I</given-names></name><name><surname>Lindner</surname><given-names>M</given-names></name><name><surname>Meiners</surname><given-names>S</given-names></name><name><surname>Eickelberg</surname><given-names>O</given-names></name><name><surname>Königshoff</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Preclinical validation and imaging of Wnt-induced repair in human 3D lung tissue cultures</article-title><source>The European Respiratory Journal</source><volume>46</volume><fpage>1150</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1183/09031936.00183214</pub-id><pub-id pub-id-type="pmid">25929950</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uphoff</surname><given-names>CC</given-names></name><name><surname>Drexler</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Detection of Mycoplasma contamination in cell cultures</article-title><source>Current Protocols in Molecular Biology</source><volume>106</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1002/0471142727.mb2804s106</pub-id><pub-id pub-id-type="pmid">24733240</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valapour</surname><given-names>M</given-names></name><name><surname>Lehr</surname><given-names>CJ</given-names></name><name><surname>Skeans</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>JM</given-names></name><name><surname>Uccellini</surname><given-names>K</given-names></name><name><surname>Goff</surname><given-names>R</given-names></name><name><surname>Foutz</surname><given-names>J</given-names></name><name><surname>Israni</surname><given-names>AK</given-names></name><name><surname>Snyder</surname><given-names>JJ</given-names></name><name><surname>Kasiske</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>OPTN/SRTR 2018 Annual Data Report: Lung</article-title><source>American Journal of Transplantation</source><volume>20 Suppl s1</volume><fpage>427</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1111/ajt.15677</pub-id><pub-id pub-id-type="pmid">31898416</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Amerongen</surname><given-names>R</given-names></name><name><surname>Fuerer</surname><given-names>C</given-names></name><name><surname>Mizutani</surname><given-names>M</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Wnt5a can both activate and repress Wnt/β-catenin signaling during mouse embryonic development</article-title><source>Developmental Biology</source><volume>369</volume><fpage>101</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2012.06.020</pub-id><pub-id pub-id-type="pmid">22771246</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Ly</surname><given-names>D</given-names></name><name><surname>Low</surname><given-names>RRJ</given-names></name><name><surname>Frölich</surname><given-names>S</given-names></name><name><surname>Bartolec</surname><given-names>TK</given-names></name><name><surname>Kafer</surname><given-names>GR</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name><name><surname>Gaus</surname><given-names>K</given-names></name><name><surname>Cesare</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Telomere Loop Dynamics in Chromosome End Protection</article-title><source>Molecular Cell</source><volume>71</volume><fpage>510</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.06.025</pub-id><pub-id pub-id-type="pmid">30033372</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>HP</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Feghali-Bostwick</surname><given-names>CA</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ifedigbo</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Oury</surname><given-names>TD</given-names></name><name><surname>Kaminski</surname><given-names>N</given-names></name><name><surname>Choi</surname><given-names>AMK</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>2895</fpage><lpage>2906</lpage><pub-id pub-id-type="doi">10.1084/jem.20061536</pub-id><pub-id pub-id-type="pmid">17178917</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kuan</surname><given-names>PJ</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>Cronkhite</surname><given-names>JT</given-names></name><name><surname>Torres</surname><given-names>F</given-names></name><name><surname>Rosenblatt</surname><given-names>RL</given-names></name><name><surname>DiMaio</surname><given-names>JM</given-names></name><name><surname>Kinch</surname><given-names>LN</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Garcia</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer</article-title><source>American Journal of Human Genetics</source><volume>84</volume><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2008.11.010</pub-id><pub-id pub-id-type="pmid">19100526</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>Averick</surname><given-names>M</given-names></name><name><surname>Bryan</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>McGowan</surname><given-names>L</given-names></name><name><surname>François</surname><given-names>R</given-names></name><name><surname>Grolemund</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Hester</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name><name><surname>Bache</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name><name><surname>Ooms</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Seidel</surname><given-names>D</given-names></name><name><surname>Spinu</surname><given-names>V</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Vaughan</surname><given-names>D</given-names></name><name><surname>Wilke</surname><given-names>C</given-names></name><name><surname>Woo</surname><given-names>K</given-names></name><name><surname>Yutani</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Welcome to the Tidyverse</article-title><source>Journal of Open Source Software</source><volume>4</volume><elocation-id>1686</elocation-id><pub-id pub-id-type="doi">10.21105/joss.01686</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiese</surname><given-names>KE</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>van Amerongen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Wnt signalling: conquering complexity</article-title><source>Development (Cambridge, England)</source><volume>145</volume><elocation-id>dev165902</elocation-id><pub-id pub-id-type="doi">10.1242/dev.165902</pub-id><pub-id pub-id-type="pmid">29945986</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>DH</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>TLB</given-names></name><name><surname>Glineburg</surname><given-names>MR</given-names></name><name><surname>Hoge</surname><given-names>C</given-names></name><name><surname>Leu</surname><given-names>NA</given-names></name><name><surname>Johnson</surname><given-names>FB</given-names></name><name><surname>Lengner</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enhancing a Wnt-Telomere Feedback Loop Restores Intestinal Stem Cell Function in a Human Organotypic Model of Dyskeratosis Congenita</article-title><source>Cell Stem Cell</source><volume>19</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.05.024</pub-id><pub-id pub-id-type="pmid">27545506</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>T-LB</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>JT</given-names></name><name><surname>Jagannathan</surname><given-names>G</given-names></name><name><surname>Tobias</surname><given-names>JW</given-names></name><name><surname>Schultz</surname><given-names>DC</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lengner</surname><given-names>CJ</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Lynch</surname><given-names>JP</given-names></name><name><surname>Johnson</surname><given-names>FB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutual reinforcement between telomere capping and canonical Wnt signalling in the intestinal stem cell niche</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14766</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14766</pub-id><pub-id pub-id-type="pmid">28303901</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>C</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Carraro</surname><given-names>G</given-names></name><name><surname>Parimon</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Soukiasian</surname><given-names>HJ</given-names></name><name><surname>David</surname><given-names>G</given-names></name><name><surname>Weigt</surname><given-names>SS</given-names></name><name><surname>Belperio</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Noble</surname><given-names>PW</given-names></name><name><surname>Stripp</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Senescence of Alveolar Stem Cells Drives Progressive Pulmonary Fibrosis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/820175</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Yihui Xie</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>DT: A Wrapper of the JavaScript Library</data-title><source>DataTables</source></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Tzouvelekis</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Herazo-Maya</surname><given-names>JD</given-names></name><name><surname>Ibarra</surname><given-names>GH</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>de Castro</surname><given-names>JPW</given-names></name><name><surname>DeIuliis</surname><given-names>G</given-names></name><name><surname>Ahangari</surname><given-names>F</given-names></name><name><surname>Woolard</surname><given-names>T</given-names></name><name><surname>Aurelien</surname><given-names>N</given-names></name><name><surname>Arrojo E Drigo</surname><given-names>R</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Graham</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Scanlan</surname><given-names>TS</given-names></name><name><surname>Mannam</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>PJ</given-names></name><name><surname>Herzog</surname><given-names>EL</given-names></name><name><surname>Bianco</surname><given-names>AC</given-names></name><name><surname>Kaminski</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function</article-title><source>Nature Medicine</source><volume>24</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/nm.4447</pub-id><pub-id pub-id-type="pmid">29200204</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>enrichplot: Visualization of Functional Enrichment Result</data-title><source>Enrichplot</source></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zacharias</surname><given-names>WJ</given-names></name><name><surname>Frank</surname><given-names>DB</given-names></name><name><surname>Zepp</surname><given-names>JA</given-names></name><name><surname>Morley</surname><given-names>MP</given-names></name><name><surname>Alkhaleel</surname><given-names>FA</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Cantu</surname><given-names>E</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor</article-title><source>Nature</source><volume>555</volume><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/nature25786</pub-id><pub-id pub-id-type="pmid">29489752</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Toh</surname><given-names>L</given-names></name><name><surname>Lau</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>32494</fpage><lpage>32511</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.368282</pub-id><pub-id pub-id-type="pmid">22854964</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec id="s8" sec-type="appendix"><title>Key resources table</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">BU3 NGST</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib38">Jacob et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">iPS cell line</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">BU3 NGST – WT</td><td align="left" valign="bottom">This Paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">iPS cell line, WT control passaged with the DKC1 A386T cell line. See <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> &amp; 2 for more details. Contact the corresponding authors for the cell line.</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">BU3 NGST - DKC1 A386T</td><td align="left" valign="bottom">This Paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">iPS cell line, DKC1 A386T passaged with the WT cell line. See <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> &amp; 2 for more details. Contact the corresponding authors for the cell line.</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">AG04646</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">iPS cell line</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pX458</td><td align="left" valign="bottom">Feng Zhang</td><td align="left" valign="bottom">Addgene # 48,138</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Thiazovivin (TZV)</td><td align="left" valign="bottom">Cayman Chemical compound, drug</td><td align="left" valign="bottom">CAT# 14,245</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SB431542</td><td align="left" valign="bottom">Cayman Chemical compound, drug</td><td align="left" valign="bottom">CAT# 13,031</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dorsomorphin</td><td align="left" valign="bottom">Cayman Chemical compound, drug</td><td align="left" valign="bottom">CAT# 21,207</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CHIR99021</td><td align="left" valign="bottom">Cayman Chemical compound, drug</td><td align="left" valign="bottom">CAT# 13,122</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CHIR98014</td><td align="left" valign="bottom">Cayman Chemical compound, drug</td><td align="left" valign="bottom">CAT# 15,578</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Retinoic Acid</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">CAT# R2625-50MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">rhBMP4</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">CAT# 314 BP-050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">rhKGF</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">CAT# 251 KG-050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dexamethasone</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">CAT# D4902-100MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="hyphen" valign="bottom">8Br-cAMP</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">CAT# 7880–250 MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IBMX</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">CAT# I5879-250MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">DNaseI</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">CAT# 4716728001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="hyphen" valign="bottom">7-AAD</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">CAT# 51-68981E</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Propidium Iodide</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">CAT# 556,463</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Dispase II</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 17105041</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SYBR Green I Nucleic Acid Gel Stain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">CAT# S7563</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Matrigel, Growth Factor Reduced</td><td align="left" valign="bottom">Corning</td><td align="left" valign="bottom">CAT# 354,230</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Stem MACS iPS-Brew XF</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">CAT# 130-104-368</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Accutase</td><td align="left" valign="bottom">Innovative Cell Technologies</td><td align="left" valign="bottom">CAT# AT104-500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">P3 Primary Cell 4D-NucleofectorTM X Kit L</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">CAT# V4XP-3012</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IMDM</td><td align="left" valign="bottom">Corning/Mediatech</td><td align="left" valign="bottom">CAT# MT10-016-CV</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ham’s F12 Nutrient Mix</td><td align="left" valign="bottom">Corning/Mediatech</td><td align="left" valign="bottom">CAT# MT10-080-CV</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">B27</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 17504044</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">N2</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 17502048</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BSA Fraction V</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 15260037</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Monothioglycerol</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">CAT# M6145-25ML</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GlutaMAX</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 35050061</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ascorbic Acid</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">CAT# A4544-25G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Primocin</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">CAT# ANT-PM-2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hank’s Balanced Salt Solution</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 14175079</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 15630080</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">EDTA</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 15575039</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">0.05% trypsin-EDTA</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">CAT# 25300054</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Direct-zol RNA Micro Kit</td><td align="left" valign="bottom">Zymo</td><td align="left" valign="bottom">CAT# R2061</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Gentra Puregene Cell Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">CAT# 158,745</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-NANOG (Rabbit polyclonal)</td><td align="left" valign="bottom">Reprocell/Stemgent</td><td align="left" valign="bottom">CAT# 09–0020</td><td align="left" valign="bottom">IF (1:100 37°C for 2 hr)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-53BP1 (Rabbit monoclonal)</td><td align="left" valign="bottom">Novus</td><td align="left" valign="bottom">CAT# NB100-304</td><td align="left" valign="bottom">IF (1:100 37°C for 2 hr)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-P21 (Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">CAT# sc-6246</td><td align="left" valign="bottom">IF (1:50 37°C for 2 hr)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Cleaved Caspase 3 (CC3) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">CAT# 9,664</td><td align="left" valign="bottom">IF (1:2000 37°C for 2 hr)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Anti-Cy3-Telo-C Probe</td><td align="left" valign="bottom">PNA Bio</td><td align="left" valign="bottom">CAT# F1002</td><td align="left" valign="bottom">Anti-telomeric</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Digoxigenin-AP, Fab fragments</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">CAT# 11093274910</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Rabbit IgG Secondary Antibody, Alexa Fluor 647 (Donkey polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">CAT# A-21244</td><td align="left" valign="bottom">IF (1:250 RT for 1 hr)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-Mouse IgG Secondary Antibody, Alexa Fluor 647 (Donkey polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">CAT# A-31571</td><td align="left" valign="bottom">IF (1:250 RT for 1 hr)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-Goat IgG Secondary Antibody, Alexa Fluor 647 (Donkey polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">CAT# A-21447</td><td align="left" valign="bottom">IF(1:250 RT for 1 hr)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TriZOL</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">CAT# 15596018</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FailSafe Polymerase Enzyme Mix</td><td align="left" valign="bottom">Lucigen</td><td align="left" valign="bottom">CAT# FS9901K</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FailSafe Buffer H</td><td align="left" valign="bottom">Lucigen</td><td align="left" valign="bottom">CAT# FSP995H-INCL</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CviAII</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">CAT# R0640L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">BfaI</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">CAT# R0568L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">MseI</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">CAT# R0525L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">NdeI</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">CAT# R0111L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">rSAP</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">CAT# M0371L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CDP-Star</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">CAT# 11759051001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DIG-11-dUTP</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">CAT# 11558706910</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DIG Easy Hybridization Granules</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">CAT# 11796895001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Blocking Reagent</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">CAT# 11096176001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DIG Labeld DNA Molecular Weight Marker II</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">CAT# 11218590910</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hybond-XL</td><td align="left" valign="bottom">Cytiva/Amersham</td><td align="left" valign="bottom">CAT# RPN303S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Klenow Fragment</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">CAT# M0212S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Lambda Exonuclease</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">CAT# M0262S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Go-TAQ Flexi</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">CAT# M8298</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">ddPCR Multiplex Supermix</td><td align="left" valign="bottom">BioRad</td><td align="left" valign="bottom">CAT# 12005909</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">FIJI</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.net/Fiji">https://imagej.net/Fiji</ext-link></td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Salmon</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib81">Patro et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Ingenuity pathway analysis</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib52">Krämer et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">ImageQuant TL 8.2</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018374">SCR_018374</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">TeSLAQuant</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></sec></app><app id="appendix-2"><title>Appendix 2</title><sec id="s9" sec-type="appendix"><title>Primer Sequences</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-DKC1A386-5-F</td><td align="left" valign="bottom">This Paper</td><td align="left" valign="bottom">gRNA Cloning Primers designed to target DKC1 A386 – See <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> for details</td><td align="left" valign="bottom">CAC CGC TTC TTC TGA CTT GCC TGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-DKC1A386-5-R</td><td align="left" valign="bottom">This Paper</td><td align="left" valign="bottom">gRNA Cloning Primers designed to target DKC1 A386 – See Figure 1—figure supplement 1 for details</td><td align="left" valign="bottom">AAA CCC AGG CAA GTC AGA AGA AGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DKC1-Geno-F</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref></td><td align="left" valign="bottom">Genotyping primers for DKC1 Gene</td><td align="left" valign="bottom">AAA AGT AGA GTG GCT GCG GT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DKC1-Geno-R</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib114">Woo et al., 2016</xref></td><td align="left" valign="bottom">Genotyping primers for DKC1 Gene</td><td align="left" valign="bottom">ACA ACC TCC ATG CTC ACC TG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA-T1</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom">Telorette</td><td align="left" valign="bottom">ACT GGC CAC GTG TTT TGA TCG ACC CTA AC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA-T2</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom">Telorette</td><td align="left" valign="bottom">ACT GGC CAC GTG TTT TGA TCG ATA ACC CT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA-T3</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom">Telorette</td><td align="left" valign="bottom">ACT GGC CAC GTG TTT TGA TCG ACC TAA CC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA-T4</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom">Telorette</td><td align="left" valign="bottom">ACT GGC CAC GTG TTT TGA TCG ACT AAC CC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA-T5</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom">Telorette</td><td align="left" valign="bottom">ACT GGC CAC GTG TTT TGA TCG AAA CCC TA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA-T6</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom">Telorette</td><td align="left" valign="bottom">ACT GGC CAC GTG TTT TGA TCG AAC CCT AA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA Adapter Short</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">GGT TAC TTT GTA AGC CTG TC[SpcC3]</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA Adapter TA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">[Phos] TAG ACA GGC TTA CAA AGT AAC CAT GGT GGA GAA TTC TGT CGT CTT CAC GCT ACA TT [SpcC3]</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA Adapter AT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">[Phos] ATG ACA GGC TTA CAA AGT AAC CAT GGT GGA GAA TTC TGT CGT CTT CAC GCT ACA TT [SpcC3]</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">AP</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">TGT AGC GTG AAG ACG ACA GAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TeSLA-TP</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lai et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">TGG CCA CGT GTT TTG ATC GA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">G-Rich ONT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib55">Lai et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">[Phos] CCC TAA CCC TAA CCC TAA CCC TAA CCC TAA CCC TAA CCC TAG ATA GTT GAG AGT C</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Branched Universal Sequence-based reagent</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib55">Lai et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">[Phos] GAC TCT CAA CTA TC +T + A</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TS</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib35">Herbert et al., 2006</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">AAT CCG TCG AGC AGA GTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACX</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib35">Herbert et al., 2006</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">GCG CGG CTT ACC CTT ACC CTT ACC CTA ACC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tel1B</td><td align="char" char="." valign="bottom">Luo et al. 2020</td><td align="left" valign="bottom"/><td align="left" valign="bottom">CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tel2B</td><td align="char" char="." valign="bottom">Luo et al. 2020</td><td align="left" valign="bottom"/><td align="left" valign="bottom">GGC TTG CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">HBG1</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib13">Cawthon, 2002</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">GCT TCT GAC ACA ACT GTG TTC ACT AGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">HBG2</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib13">Cawthon, 2002</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">CAC CAA CTT CAT CCA CGT TCA CC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TINF2</td><td align="left" valign="bottom">BioRad</td><td align="left" valign="bottom">dHsaCPE5027564</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">POT1</td><td align="left" valign="bottom">BioRad</td><td align="left" valign="bottom">dHsaCPE50447370</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TERT</td><td align="left" valign="bottom">BioRad</td><td align="left" valign="bottom">dHsaCPE5048434</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TERC</td><td align="left" valign="bottom">BioRad</td><td align="left" valign="bottom">dHsaCNS923142164</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACTB</td><td align="left" valign="bottom">BioRad</td><td align="left" valign="bottom">dHsaCPE5190200</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64430.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dang</surname><given-names>Weiwei</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Baylor College of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2020.10.28.358887" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2020.10.28.358887"/></front-stub><body><p>This study reports a new cell line model for Dyskeratosis congenita. The authors characterized this model by examining its ability to form organoids and its defects in telomeres. Transcriptomics analysis unveiled defects in Wnt signaling, and treatment with a Wnt agonist could rescue these defects and enhance telomerase activity. Overall, the study is well designed and executed, the data presented are clear and convincing and the conclusions should be of great interest to researchers studying Dyskeratosis congenita and telomere biology.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64430.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dang</surname><given-names>Weiwei</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Baylor College of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2020.10.28.358887">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.10.28.358887v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;GSK3 inhibition rescues growth and telomere dysfunction in dyskeratosis congenita iPSC-derived type II alveolar cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Matt Kaeberlein as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The mutant cells showed down-regulation of shelterin component genes (TINF2 and POT1) downstream of the Wnt signaling pathway. To show that the GSK3 inhibitor CHIR99021 acted through Wnt signaling in iAT2 cells, the authors should show that the expression of these genes can be restored by the treatment.</p><p>2) the authors use iPSCs that are 5 vs 25 passages after introduction (or not) of the DKC1 A386T mutation for the generation of iAT2 cells. The data presented in Figure S3D simply does not correspond to the statement that &quot;using iPSCs only five passages after the introduction of the mutation yielded iAT2s without any defects in alveolosphere growth or size at D70 (Figure S3C)&quot; as the images in Figure S3D appear clearly distinguishable. the iPSCs 5 passages after gene editing may certainly be less effected, which would not take away from the authors may point (it is not the DKC1 A386T mutation per se). The manuscript needs to either include rigorous data as in Figure 1C and/or 1D or render a qualitive assessment that is better supported by the data presented.</p><p>3) The authors show iAT2 DKC1 mutant organoids generated from the later passage iPSCs have an apparent growth defect as early as Day 50 but that those generated from the earlier passage iPSCs do not at Day 70 [with caveats the images are of different quality (comparing Figure 1B and Figure S3D) and quantitative data (similar to Figure 1C) are lacking for the iAT2 organoids generated from the early passage iPSCs]. This needs to be addressed. Is it possible that there are two different processes – an initial constraint imposed by shortened telomeres (D50) and then a more catastrophic effect due to uncapping (D70)?</p><p>4) It is striking that prolonged CHIR99021 treatment (ie, through to Day 70) resulted in increased telomerase activity, and more so in mutant compared to wild type cells. First, how reproducible was this effect? Given TERT expression does not rescue DKC1 mutants but TERC does, were TERC levels increased? Also, given this robust increase, its striking that no difference is detected in TeSLA assays given the proportion of very short detected telomeres that would presumably be substrates for telomerase.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>– The analysis shown in Figure 1C should be done for the experiment performed with iPSCs 5 passages after introduction of the DKC1 A386T mutation.</p><p>– An apoptosis positive control is lacking for Figure S3E.</p><p>– The figure legend for Figure S4B does not make sense nor correlate with the main text description (lines 209-211). It appears that an experiment was designed whereby CHIR99021 was either present or removed after D56 and the cells analyzed at D70 (Figure S4A) but the data are not shown in Figure S4B.</p><p>– The graphics Figure 1A and S3C show Day 49 but the text reads Day 50 – this is confusing.</p><p>– It is not stated whether the analyses performed in Figure 2 are using cells derived from iPSCs 25 passages after introduction of the DKC1 mutation (It is likely this is the case, but it should be clearly stated).</p><p>– Line 138 – Should refer to Figure S3C-D.</p><p>– The methods section should be carefully reviewed for formatting consistency throughout – e.g.., use of capitalization or not.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. The mutant cells showed down-regulation of shelterin component genes (TINF2 and POT1) downstream of the Wnt signaling pathway. To show that the GSK3 inhibitor CHIR99021 acted through Wnt signaling in iAT2 cells, the authors should show that the expression of these genes can be restored by the treatment.</p><p>2. Is Wnt signaling required for CHIR99021 to show its effects on cellular senescence and telomere dysfunction? This should be examined and discussed.</p><p>3. The authors showed little change in telomere length, but increased telomerase activity by CHIR99021 treatment in iAT2 cells. Some further discussion on this will be helpful for readers to understand why this is the case.</p><p>4. Wnt has been shown to regulate TERT expression. Hence, it should be tested here whether increased telomerase activity is attributed to increased TERT expression and/or TERC expression.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64430.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The mutant cells showed down-regulation of shelterin component genes (TINF2 and POT1) downstream of the Wnt signaling pathway. To show that the GSK3 inhibitor CHIR99021 acted through Wnt signaling in iAT2 cells, the authors should show that the expression of these genes can be restored by the treatment.</p></disp-quote><p>We agree that this is an interesting issue and that demonstrating restoration of shelterin expression by CHIR would support the hypothesis that changes in shelterin levels are involved in the mechanism by which CHIR rescues defects in the mutant iAT2 cells. We have attempted to demonstrate this using two approaches*, but unfortunately have been unable to do so. We are sorry about this (and want to emphasize that it has been very difficult to make these attempts under the conditions of the pandemic, particularly given the months-long cultures needed to do experiments along with unpredictable lab shut downs, as well as supply chain issues (particularly Matrigel shortages)). Regardless, we want to emphasize three things: 1) we haven’t claimed that shelterin upregulation is involved in rescue, 2) whether or not we know the precise mechanism of rescue doesn’t affect the overall findings of our paper nor the potential therapeutic relevance of the rescue, and 3) we now provide new and clearer data supporting a role for differences in telomerase expression and activity (which are well-known to be upregulated by Wnt in diverse contexts) as contributors to mutant defects and to the rescue by CHIR (see Point 4, below).</p><p>­­– In particular, we compared mRNA transcript levels in wild type and mutant iAT2 cultures under basal and rescued conditions using both scRNAseq and ddPCR assays. Unfortunately, we had technical problems with the scRNAseq and have so far been unable to repeat the experiment. The ddPCR data was too variable under rescued conditions to be interpretable, and we ran out of RNA before getting satisfactory results (but fortunately the ddPCR did provide clear data comparing wild type and mutant cultures under basal conditions, now provided in Figure 3—figure supplement 1). We will eventually repeat the scRNAseq, but we feel such analyses are really outside the scope of the manuscript.</p><disp-quote content-type="editor-comment"><p>2) The authors use iPSCs that are 5 vs 25 passages after introduction (or not) of the DKC1 A386T mutation for the generation of iAT2 cells. The data presented in Figure S3D simply does not correspond to the statement that &quot;using iPSCs only five passages after the introduction of the mutation yielded iAT2s without any defects in alveolosphere growth or size at D70 (Figure S3C)&quot; as the images in Figure S3D appear clearly distinguishable. the iPSCs 5 passages after gene editing may certainly be less effected, which would not take away from the authors may point (it is not the DKC1 A386T mutation per se). The manuscript needs to either include rigorous data as in Figure 1C and/or 1D or render a qualitive assessment that is better supported by the data presented.</p></disp-quote><p>We appreciate these concerns and have updated the manuscript to offer a qualitative assessment that more accurately reflects the data. Furthermore, we quantified the organoid formation efficiency for the iAT2s derived from passage 5 iPSCs (see Figure 1—figure supplement 4 A-C).</p><p>In particular, the modified sentence reads as follows: “In contrast, using iPSCs only five passages after the introduction of the mutation yielded iAT2s with less dramatic defects in alveolosphere growth and size at D70 (Figure S3C-E).”</p><disp-quote content-type="editor-comment"><p>3) The authors show iAT2 DKC1 mutant organoids generated from the later passage iPSCs have an apparent growth defect as early as Day 50 but that those generated from the earlier passage iPSCs do not at Day 70 [with caveats the images are of different quality (comparing Figure 1B and Figure S3D) and quantitative data (similar to Figure 1C) are lacking for the iAT2 organoids generated from the early passage iPSCs]. This needs to be addressed. Is it possible that there are two different processes – an initial constraint imposed by shortened telomeres (D50) and then a more catastrophic effect due to uncapping (D70)?</p></disp-quote><p>We agree that there is a progressive defect with passage. This observation is consistent with a substantial body of literature in the telomere field, and is likely explained by two phenomena:</p><p>First, although the rate of telomere shortening is gradual at the level of a population of cells (each with its own collection of 92 telomeres), this rate is somewhat stochastic for any given telomere (e.g. a telomere can shorten dramatically and instantaneously due to an error during DNA replication), leading some cells to begin experiencing growth restriction earlier than other cells. Thus, at the level of a population of cells, growth declines in gradual fashion as an increasing fraction of the population becomes senescent. E.g. see Stochasticity of Telomere Shortening dictates Culture Senescence in Fibroblasts (Martin-Ruiz et al., 2004) and The replicometer is broken: telomeres activate cellular senescence in response to genotoxic stresses (Suram and Herbig, 2014).</p><p>Second, there is clear evidence that telomeres do not lose their functions in an “all or none” fashion as they shorten. For example, partially shortened telomeres can activate ATM (and thus senescence) prior to the stage at which telomeres that have shortened even further become fusogenic. It is also thought (but not yet proven) that as telomeres shorten below a particular threshold length, the tendency to activate DNA damage responses may increase in a somewhat graded fashion with additional shortening (e.g. perhaps by impacting the equilibrium between telomeres in linear vs. t-loop conformations). Therefore, it is conceivable that gradual telomere shortening may increasingly inhibit cell cycle progression. E.g. see (Cesare et al., 2009, 2013; Kaul et al., 2011; Ruis and Boulton, 2021a; Van Ly et al., 2018a).</p><p>We have modified the Discussion to highlight our thoughts on these points with a new text, as follows:</p><p>“Senescence of the mutant iAT2 cells displayed a senescent phenotype that manifested only after serial passaging and telomere shortening, demonstrating that the senescence is not a direct result of <italic>DKC1</italic> mutation <italic>per se</italic>. The senescence-associated growth defect emerged gradually, becoming more pronounced at later passages. Similarly gradual onset of telomere-driven senescence has been observed in other settings, and has been attributed to i) the stochastic nature of telomere shortening (causing some cells in a population to senesce prior to others) and ii) graded increases in DNA damage-responses in proportion to the extent of telomere shortening (Cesare et al., 2009, 2013; Kaul et al., 2011; Martin-Ruiz et al., 2004; Ruis and Boulton, 2021b; Suram and Herbig, 2014; Van Ly et al., 2018b).”</p><disp-quote content-type="editor-comment"><p>4) It is striking that prolonged CHIR99021 treatment (ie, through to Day 70) resulted in increased telomerase activity, and more so in mutant compared to wild type cells. First, how reproducible was this effect? Given TERT expression does not rescue DKC1 mutants but TERC does, were TERC levels increased? Also, given this robust increase, its striking that no difference is detected in TeSLA assays given the proportion of very short detected telomeres that would presumably be substrates for telomerase.</p></disp-quote><p>We agree that this finding was striking (and surprising), and upon repetition we noticed that the WT organoids were at a much higher level of confluence than the <italic>DKC1</italic> mutant organoids when they were assayed for telomerase activity. Given the well-established general upregulation of telomerase activity in cycling cells, it seemed likely that the relative unresponsiveness of the WT cells to CHIR was explained by their relatively diminished freedom to divide under these conditions. Indeed, upon repeating the experiment at lower cell densities, which permitted proliferation of both genotypes, we observed upregulation of telomerase activity with CHIR in both genotypes, with more dramatic upregulation in the mutant cultures but only up to the same absolute level as WT (i.e. CHIR restored telomerase levels to that of WT). We have updated the manuscript to reflect this data (Figure 4 G). This doesn’t impact the major conclusions of the study, and still indicates that upregulation of telomerase activity contributes to the rescue by CHIR99021 of mutant organoid growth.</p><p>The reviewer is correct that TERC overexpression rescues telomerase activity in <italic>DKC1</italic> mutant cells. But it is not correct that it has been shown that elevated TERT do not provide rescue in these mutant. Indeed, when TERT levels are limiting, artificial expression of TERT does enhance telomerase activity in <italic>DKC1</italic> mutant cells (Wong and Collins, 2006) (See Figure 1 of Wong and Collins 2006). While we have not directly tested if TERT levels are limiting in our cultured iAT2 cells, it is likely that they are like most other human cell types where TERT levels are limiting. With regard to <italic>TERC,</italic> although we were able to discern a clear decrease in <italic>TERC</italic> (and <italic>TERT</italic>) mRNA levels in the mutant iAT2 cells by ddPCR (see Figure 3—figure supplement 1), technical limitations (described above in Point 1) prevented us from establishing clear rescue of <italic>TERC</italic> levels under conditions of rescue by CHIR99021. However, given that <italic>TERC</italic> levels are generally upregulated by Myc, and that Myc is generally upregulated by GSK3 inhibition, there is a good possibility that CHIR99021 does indeed upregulate <italic>TERC</italic> levels, which could also contribute to the elevated telomerase activity. Regardless of the underlying mechanisms, the restoration of telomerase activity by GSK3 inhibition is of potential translational therapeutic importance.</p><p>We agree that the lack of telomere lengthening by TeSLA is surprising, as it is not what our group has seen previously with intestinal organoids with similar mutations. As we mentioned in the manuscript, we cannot rule out lengthening of the shortest telomeres that are too short to be detected by TeSLA. We also note that mean telomere lengths were actually increased by ~20%. Finally, TERT may be enhancing capping without lengthening by binding to uncapped telomeres and displacing DDR factors (Perera et al., 2019).</p><p>To address the above issues, we have modified the Results section as follows:</p><p>“We ultimately investigated how CHIR99021 affects the telomere status of DC iAT2s. CHIR treated iAT2 cells showed fewer cells with 53BP1 foci, fewer p21+ cells and fewer TIF+ cells (Figure 4 D-F). TeSLA revealed a modest increase in average telomere length but no apparent decrease in the frequency of shortest detectable telomeres (Figure 4—figure supplement 3 A-C). iAT2 cell telomerase activity was restored in mutant cells treated with CHIR99021 to levels similar to those seen in WT cells (Figure 4G). Together, these data argue that GSK3 inhibition not only rescues the growth of DC iAT2 cells, but it also rescues telomere defects, most likely through upregulation of telomerase activity that could extend telomeres that are shorter than those that can be detected by TeSLA; it is also possible that telomerase is contributing to telomere capping via lengthening-independent mechanisms (Perera et al., 2019). Of note, withdrawal of CHIR99021 during only the 14 days prior to D70 was sufficient to elicit the growth defect (Figure 4—figure supplement 1 A-B), consistent with an only modest increase in telomere length associated with the increased telomerase activity.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>– The analysis shown in Figure 1C should be done for the experiment performed with iPSCs 5 passages after introduction of the DKC1 A386T mutation.</p></disp-quote><p>Please see our response above to Essential Revision 2. Furthermore, we have quantified organoid formation efficiency for the cultures derived from passage 5 iPSCs, as requested (see Figure S3E), and as expected, the efficiencies are indistinguishable between the wild type and mutant cultures. We were unable to accurately quantify organoid areas given the quality of the images we obtained for these particular cultures, but numerous direct observations never revealed any obvious differences in organoid sizes between wild type and mutant under these conditions.</p><disp-quote content-type="editor-comment"><p>– An apoptosis positive control is lacking for Figure S3E.</p></disp-quote><p>We appreciate this suggestion, and we have added a positive control to Figure 2—figure supplement 1 C and explained it in detail within the figure legend.</p><disp-quote content-type="editor-comment"><p>– The figure legend for Figure S4B does not make sense nor correlate with the main text description (lines 209-211). It appears that an experiment was designed whereby CHIR99021 was either present or removed after D56 and the cells analyzed at D70 (Figure S4A) but the data are not shown in Figure S4B.</p></disp-quote><p>We agree that the figure legend may not adequately reflect the data presented and the main text. We have included your suggestions and believe they help clarify the experiment performed. To simplify presentation of data, previous Figure S4 has been divided into new Figure 4—figure supplements 1, 2 and 3, and the relevant data is in the Figure 4—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>– The graphics Figure 1A and S3C show Day 49 but the text reads Day 50 – this is confusing.</p></disp-quote><p>We appreciate how this might be confusing and have changed references to Day 49 to Day 50.</p><disp-quote content-type="editor-comment"><p>– It is not stated whether the analyses performed in Figure 2 are using cells derived from iPSCs 25 passages after introduction of the DKC1 mutation (It is likely this is the case, but it should be clearly stated).</p></disp-quote><p>We have changed the heading titles as well as the figure titles to reflect this more clearly.</p><disp-quote content-type="editor-comment"><p>– Line 138 – Should refer to Figure S3C-D.</p></disp-quote><p>We agree and have changed the reference to the supplementary figures.</p><disp-quote content-type="editor-comment"><p>– The methods section should be carefully reviewed for formatting consistency throughout – e.g.., use of capitalization or not.</p></disp-quote><p>We appreciate the reviewer’s suggestion and have made the requested edits to the experimental procedures section.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. The mutant cells showed down-regulation of shelterin component genes (TINF2 and POT1) downstream of the Wnt signaling pathway. To show that the GSK3 inhibitor CHIR99021 acted through Wnt signaling in iAT2 cells, the authors should show that the expression of these genes can be restored by the treatment.</p></disp-quote><p>See our response to essential revision 4 above.</p><disp-quote content-type="editor-comment"><p>2. Is Wnt signaling required for CHIR99021 to show its effects on cellular senescence and telomere dysfunction? This should be examined and discussed.</p></disp-quote><p>We are unsure of precisely what the reviewer is asking for here, but we imagine that they might be thinking of a couple of different and important issues. First, we want to address the possibility that CHIR99021 might have non-GSK3 dependent effects (i.e. how specific an inhibitor of GSK3 is CHIR99021)? To our knowledge, it is the most selective GSK3 inhibitor available (An et al., 2012), and we direct the reviewers to the original paper addressing this issue which shows it is &gt;500-fold selective for GSKs as compared to many other kinases (Ring et al., 2003). Furthermore, the fact that we observe similar rescue with a different GSK3 inhibitor (CHIR98014) supports a role for GSK3 (and thus Wnt). Second, we want to address the possibility that the precise nature of GSK3 inhibition by CHIR99021 vs. that by Wnt might cause different effects downstream of GSK3. There are indeed multiple different possible downstream effects of the inhibition of GSK3, and it’s conceivable that these are impacted differentially by different GSK3 inhibitors. We don’t know the answer to this question, but as we describe in the manuscript, the <italic>DKC1</italic> mutation induces transcriptional changes in the Wnt pathway and CHIR99021 rescues the growth and telomere phenotypes. Furthermore, CHIR99021 is commonly used to replace Wnt ligands in multiple different differentiation protocols (Loh et al., 2016; Pagliuca et al., 2014; Rezania et al., 2014; Teo et al., 2014), supporting its similarity to Wnts. However, we are aware that canonical Wnts and CHIR99021 are not exactly the same in terms of their activation kinetics (Massey et al., 2019), and don’t discount the possibility that this could impact effects on downstream targets. These are important issues under active investigation, but we feel that they are outside the scope of our manuscript.</p><p>We now include these important caveats in the Discussion, as follows:</p><p>“We note that the effects of CHIR99021 could differ in some ways from canonical Wnt signaling, e.g. by impacting targets other than GSK3 or by differentially affecting the numerous pathways that are downstream of GSK3. However, the Wnt-related transcriptional changes in the mutant iAT2s, the high selectivity of CHIR99021 for GSK3 and its common use as a replacement for Wnt ligands in cell culture differentiation protocols, along with the fact that two different GSK3 inhibitors rescued growth of the mutant iAT2s suggest that the rescue provided by CHIR99021 is indeed related to GSK3 and Wnt (An et al., 2012; Loh et al., 2016; Pagliuca et al., 2014; Rezania et al., 2014; Ring et al., 2003; Teo et al., 2014).”</p><disp-quote content-type="editor-comment"><p>3. The authors showed little change in telomere length, but increased telomerase activity by CHIR99021 treatment in iAT2 cells. Some further discussion on this will be helpful for readers to understand why this is the case.</p></disp-quote><p>Thank you for this suggestion. Please see our response to Essential Revision 4, above.</p><p>The most relevant part of that response is reproduced here:</p><disp-quote content-type="editor-comment"><p>“We agree that the lack of telomere lengthening by TeSLA is surprising, as it is not what our group has seen previously with intestinal organoids with similar mutations. As we mentioned in the manuscript, we cannot rule out lengthening of the shortest telomeres that are too short to be detected by TeSLA. We also note that mean telomere lengths were actually increased by ~20%. Finally, TERT may be enhancing capping without lengthening by binding to uncapped telomeres and displacing DDR factors (Perera et al., 2019).”</p><p>4. Wnt has been shown to regulate TERT expression. Hence, it should be tested here whether increased telomerase activity is attributed to increased TERT expression and/or TERC expression.</p></disp-quote><p>Again, please see our response to Essential Revision 4, above.</p><p>In particular, as the reviewer points out, it is well established that TERT is Wnt target gene in diverse contexts, and its upregulation presumably contributes to the increase in telomerase activity that we observe in CHIR-treated cultures. Nonetheless, given that <italic>TERC</italic> levels are generally upregulated by Myc, and that Myc is generally upregulated by GSK3 inhibition, there is a good possibility that CHIR does indeed upregulate <italic>TERC</italic> levels, which could also contribute to the elevated telomerase activity.</p><p>References</p><p>An, W.F., Germain, A.R., Bishop, J.A., Nag, P.P., Metkar, S., Ketterman, J., Walk, M., Weiwer, M., Liu, X., Patnaik, D., et al. (2012). Discovery of Potent and Highly Selective Inhibitors of GSK3b. In Probe Reports from the NIH Molecular Libraries Program, (Bethesda (MD): National Center for Biotechnology Information (US)),.</p><p>Cesare, A.J., Kaul, Z., Cohen, S.B., Napier, C.E., Pickett, H.A., Neumann, A.A., and Reddel, R.R. (2009). Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat. Struct. Mol. Biol. <italic>16</italic>, 1244–1251.</p><p>Cesare, A.J., Hayashi, M.T., Crabbe, L., and Karlseder, J. (2013). The telomere deprotection response is functionally distinct from the genomic DNA damage response. Mol. Cell <italic>51</italic>, 141–155.</p><p>Kaul, Z., Cesare, A.J., Huschtscha, L.I., Neumann, A.A., and Reddel, R.R. (2011). Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep. <italic>13</italic>, 52–59.</p><p>Loh, K.M., Chen, A., Koh, P.W., Deng, T.Z., Sinha, R., Tsai, J.M., Barkal, A.A., Shen, K.Y., Jain, R., Morganti, R.M., et al. (2016). Mapping the Pairwise Choices Leading from Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types. Cell <italic>166</italic>, 451–467.</p><p>Martin-Ruiz, C., Saretzki, G., Petrie, J., Ladhoff, J., Jeyapalan, J., Wei, W., Sedivy, J., and von Zglinicki, T. (2004). Stochastic variation in telomere shortening rate causes heterogeneity of human fibroblast replicative life span. J. Biol. Chem. <italic>279</italic>, 17826–17833.</p><p>Massey, J., Liu, Y., Alvarenga, O., Saez, T., Schmerer, M., and Warmflash, A. (2019). Synergy with TGFβ ligands switches WNT pathway dynamics from transient to sustained during human pluripotent cell differentiation. Proc. Natl. Acad. Sci. U. S. A. <italic>116</italic>, 4989–4998.</p><p>Pagliuca, F.W., Millman, J.R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J.H., Peterson, Q.P., Greiner, D., and Melton, D.A. (2014). Generation of functional human pancreatic β cells in vitro. Cell <italic>159</italic>, 428–439.</p><p>Perera, O.N., Sobinoff, A.P., Teber, E.T., Harman, A., Maritz, M.F., Yang, S.F., Pickett, H.A., Cesare, A.J., Arthur, J.W., MacKenzie, K.L., et al. (2019). Telomerase promotes formation of a telomere protective complex in cancer cells. Sci Adv <italic>5</italic>, eaav4409.</p><p>Rezania, A., Bruin, J.E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O’Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. <italic>32</italic>, 1121–1133.</p><p>Ring, D.B., Johnson, K.W., Henriksen, E.J., Nuss, J.M., Goff, D., Kinnick, T.R., Ma, S.T., Reeder, J.W., Samuels, I., Slabiak, T., et al. (2003). Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes <italic>52</italic>, 588–595.</p><p>Ruis, P., and Boulton, S.J. (2021a). The end protection problem—an unexpected twist in the tail. Genes &amp; Development <italic>35</italic>, 1–21.</p><p>Ruis, P., and Boulton, S.J. (2021b). The end protection problem—an unexpected twist in the tail. Genes &amp; Development <italic>35</italic>, 1–21.</p><p>Suram, A., and Herbig, U. (2014). The replicometer is broken: telomeres activate cellular senescence in response to genotoxic stresses. Aging Cell <italic>13</italic>, 780–786.</p><p>Teo, A.K.K., Valdez, I.A., Dirice, E., and Kulkarni, R.N. (2014). Comparable generation of activin-induced definitive endoderm via additive Wnt or BMP signaling in absence of serum. Stem Cell Reports <italic>3</italic>, 5–14.</p><p>Van Ly, D., Low, R.R.J., Frölich, S., Bartolec, T.K., Kafer, G.R., Pickett, H.A., Gaus, K., and Cesare, A.J. (2018a). Telomere Loop Dynamics in Chromosome End Protection. Mol. Cell <italic>71</italic>, 510–525.e6.</p><p>Van Ly, D., Low, R.R.J., Frölich, S., Bartolec, T.K., Kafer, G.R., Pickett, H.A., Gaus, K., and Cesare, A.J. (2018b). Telomere Loop Dynamics in Chromosome End Protection. Mol. Cell <italic>71</italic>, 510–525.e6.</p><p>Wong, J.M.Y., and Collins, K. (2006). Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev. <italic>20</italic>, 2848–2858.</p></body></sub-article></article>